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 “Der Mensch ist was er isst” 
“The man is what he eats” 
Probably Ludwig Feuerbach didn’t know how much right was when in 1862 he wrote this.  
The Epigenetics is a rapidly growing research field that investigates heritable alterations in gene 
expression caused by mechanisms other than changes in DNA sequence. Many scientists are working 
on it in order to find a good definition, at the moment the proposed one reads: “an epigenetic trait is a 
stably inherited phenotype resulting from changes in a chromosome without alterations in the DNA 
sequence.” At the present we know that DNA isn’t everything, environmental factors can alter the 
way our genes are expressed. These changes can make even identical twins different, and are 
sometimes passed on to the offspring. Once nurture seemed clearly distinct from nature. Now it 
appears that our diets and lifestyles can change the expression of our genes influencing a network of 
chemical switches within our cells collectively known as the epigenome. This new understanding 
may lead us to potent new medical therapies 1. 
Introduction  
The chromatin remodeling is one of the most important 
epigenetic regulation of gene expression. Chromatin is an 
extremely complex structure that compacts eukaryotic DNA 
in the nucleus. It consists of repeating spherical particles 
termed nucleosomes. Nucleosomes are formed by the 
wrapping of 147 bp of DNA in 1.7 left-handed superhelical 
turns around a highly basic, evolutionary conserved histonic 
Figure 1 Nucleosome 
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octamer, consisting of 2 copies each of the proteins named histones H2A, H2B, H3, and H42. 
Nucleosomes are connected by short stretches of linker DNA resulting in a fiber with a diameter of 
~10 nm that has a beads-on-a-string-like appearance. Chromatin organization is regulated on various 
levels and by a multitude of diverse proteins that can act on both the DNA and histones.  
The H3 and H4 histones have long tails protruding from the nucleosome that can be modified post-
translationally by acetylation, phosphorylation, ubiquitination, and methylation, affecting their charge 
and function. Acetylation of the ε-amino groups of specific histone lysines is catalyzed by histone 
acetyltransferases (HATs) and correlates with an open chromatin structure and gene activation. 
Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine 
residues and correlates with chromatin condensation and transcriptional repression. Methylation is 
made by histone-lysine N-methyltransferase and histone-arginine N-methyltransferase (HMTs) that 
catalize the transfer of one to three methyl groups from the cofactor S-Adenosyl methionine to lysine 
and arginine residue of histone proteins. Levels of lysine methylation are known to change during 
processes such as transcriptional regulation. At the present we know that two different enzymatic 
mechanism of lysine 
demethylation are 
possible, amine 
oxidation by LSD1 
and LSD23 and 
hydroxylation by 
JmjC-domain 
containing proteins4 
(HDMs). In most 
cases, these histone- 
Figure 2 Chromatin remodeling and involved enzymes 
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3 1. HDACs, the big family 
modifying enzymes are present in multisubunit protein complexes, in which the other components are 
thought to regulate enzyme activities, modulate substrate recognition, recruit other cofactors, or carry 
out other undefined functions 5. 
1. HDACs, the big family  
Histone deacetylases (HDACs) are enzymes involved in remodelling of chromatin by deacetylating 
the histonic lysine residues, and in the regulation of mRNA stability, protein localization and 
degradation, and protein–protein and protein–DNA interactions by post-translational modifications of 
non-histone proteins 6. An aberrant activity of HDACs has been documented in several types of 
disorders as cancer 7, 8, immune and inflammatory diseases 9, neurological 10 and metabolic disorders 
11
 and many others. Because of this, HDACs have emerged as an attractive therapeutic target.  
Nineteen HDAC enzymes have been identified in humans and are categorized into four classes, based 
on sequence similarity and homology to yeast deacetylases. Class I enzymes, HDAC1, HDAC2, 
HDAC3, and HDAC8, are highly homologous to the yeast HDAC RPD312 protein, while class II 
enzymes, HDAC4, HDAC5, HDAC7, HDAC9a, HDAC9b (class IIa) and HDAC6 and HDAC10 
Figure 3 The proposed catalytic mechanism for the deacetylation of acetylated lysine. HDLP 
active-site residues and their proposed HDAC1 counterparts (in parenthesis) are labelled 
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4 1. HDACs, the big family 
(class IIb), are homologous to the yeast HDA1 protein13. HDAC11 is phylogenetically different from 
both class I and class II enzymes and is therefore classified separately as class IV.  
Class III enzymes, SIRT1-7, are an evolutionarily distinct family dependent on nicotinamide adenine 
dinucleotide (NAD+) for function and are referred to as ‘sirtuins’14. 
Classes I, II, and IV members are well-conserved zinc-dependend enzymes. Notably, class I and II 
enzymes differ in their tissue expression profiles, with class I members ubiquitously expressed, while 
class II enzymes are differentially expressed, with increased levels detectable in the heart, brain, lung, 
thymus, muscle, liver, spleen, and kidney. Differences in tissue distribution suggest differing cellular 
Figure 4. Classification of classes I, II, and IV HDACs by structure and cellular localization.  
BMC Cancer 2008, 8:243 
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5 1. HDACs, the big family 
roles for the twelve zinc-dependent HDACs; although their exact functions are not yet elucidated, 
they are likely to demonstrate considerable overlap. Analysis of available data suggests that class I 
HDACs regulate cell cycle progression 15, while class II HDACs are involved in differentiation, 
development, and osteogenesis 16. Recent work has now linked the only class IV HDAC (HDAC11) 
to a role in immune function regulation 17. HDAC6 is unique among the eleven Zn dependent 
HDACs in having two catalytic sites and an ubiquitin binding site. Specific substrates of HDAC6 
have been identified, including α-tubulin, cortacin, transmembrane proteins, such as, IFNαR, HSP90 
and other chaperone proteins and peroxiredoxins. The ubiquitin site toward the c-terminal end of 
HDAC6 plays a critical role in aggresome formation in the pathway of proteolysis of misfolded 
proteins 18. 
1.1. HDAC inhibitors 
The HDAC inhibitors (HDACi) are a group of new therapeutic agents which have a potential role in 
regulation of gene expression and induction of cell death, cell cycle arrest, and differentiation by 
altering the acetylation status of histone and non-histone proteins 19. In clinical trials, HDAC 
inhibitors have demonstrated promising antitumour activity as monotherapy in cutaneous T-cell 
lymphoma20 and other haematological malignancies 21. In solid tumours, several HDAC inhibitors 
have been shown to be efficacious as single agents 22, 23, 24; however, results of most clinical trials 
were in favour of using HDAC inhibitors either prior to the initiation of chemotherapy or in 
combination with other treatments 25, 26, 27. Two pan-HDAC inhibitors (HDACi’s), Vorinostat 
(SAHA) and Istodax (romidepsin) approved as drugs for cutaneous T-cell lymphoma (CTCL) while 
several HDACIs are currently under clinical investigation. 
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6 1. HDACs, the big family 
1.2. A long lasting story 
In 1999 M.S.Finning et al. got the crystal structures of HDLP, the A. aeolicus histone deacetylaselike 
protein (HDLP) with 35.2% identity to human HDAC1, of the HDLP+Zn2++TSA and HDLP + Zn2+ 
SAHA complexes. In this way they provided a 
framework for understanding the catalytic activity and 
inhibition of the histone deacetylase family, and 
forming a basis for the further development of HDAC 
inhibitors as antitumour agents core. The X-ray 
structure, together with the resolution of HDLP/TSA 
and HDLP/SAHA complexes, have revealed the active 
site of the enzyme but have also elucidated the 
mechanism of HDAC inhibition by hydroxamic-acid 
based inhibitors 28 HDLP has a single domain 
structure related to the open α/β class of folds. It 
contains a central eight-stranded parallel β sheet, with four α helices packed on either face. Eight 
additional α helices and large loops in the β sheet further extend the structure and result in the 
formation of a deep, narrow pocket 
with an adjacent internal cavity. 
Concisely, the catalytic core has an 
α/β motif and the active site 
consists of a tubular pocket with a 
zinc-binding site and two Asp-His 
charge-relay systems (His 131/Asp 
Figure 5 HDLP±Zn2+±TSA complex. Figure 
prepared with the programs MOLSCRIPT and 
RASTER3D 
Figure 6 HDLP residues that interact with TSA in the tubular pocket. 
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7 1. HDACs, the big family 
166 and His132/Asp173) that facilitate the acetyl cleavage of substrate by weakening the amide bond. 
The zinc cation required for the enzymatic activity is positioned near the bottom of the pocket and is 
coordinated by several histidine and aspartate residues too. Hydrophobic residues surround the 
channel leading to the bottom of the pocket, which is presumably where the aliphatic chain of the 
acetyl-lysine residue is nestled. TSA and SAHA act as substrate mimics; the aliphatic chain and 
hydroxamic acid of each inhibitor are analogous to the lysine side chain and acetyl group of the 
substrate, respectively. These inhibitors bind inside the pocket by inserting the aliphatic chain into the 
tube, making contact with the residues at the rim, walls and at the bottom of the pocket. Specifically, 
TSA contains a cap group, an aliphatic chain and a terminal hydroxamic acid functional group. The 
hydroxamic acid coordinates the zinc 
cation in a bidentate fashion (through 
CO and OH groups) and also contacts 
active-site residues (forming two 
hydrogen-bonds between its NH and 
OH groups and the two charge-relay 
systems His131/Asp166 and 
His132/Asp173, and another one 
between its CO and the Tyr297 
hydroxyl group). Moreover, hydroxamic 
acid function replaces the zinc-bound 
water molecule of the active structure 
with its OH group 29. Fitting snugly into 
the channel, the aliphatic chain makes 
several Van der Waals contacts with the channel residues. The dimethylaminophenyl group acts as a 
Figure 7 Space-filling representation of TSA in the active-site 
pocket. The hydroxamic acid group, most of the aliphatic chain 
and part of the dimethylamino-phenyl group of TSA are buried 
(60% of TSA's surface area). The internal cavity has a volume of 
144AÊ 3. 
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8 1. HDACs, the big family 
cap to pack the inhibitor at the rim of the tubular pocket-like active site. Indeed, this cap group 
contacts the residues of Pro22 and Tyr91 on the rim of the pocket and possibly mimics the amino 
acids adjacent to the acetylated lysine residue in the histone. The binding of TSA causes a 
conformational change in a tyrosine residue on this rim (Tyr91) and thereby allows tighter packing of 
the cap group. It has been postulated that this insertion and binding in the catalytic site blocks 
substrate access to the active zinc ion and, thereby, inhibits the deacetylase activity. Conservation of 
the amino acid sequences of the loops that form the active site pocket among HDLP and class I and II 
mammalian HDACs strongly suggests that the catalytic reaction and mechanism of inhibition by TSA 
and SAHA are the same in HDACs as HDLP 29.  
The catalytic domains of the known class I and II human HDACs are very well conserved, but there 
are certain 
differences 
that may allow 
for the 
production of 
specific 
inhibitors. 
Most of the 
residues that 
are seen in the 
HDLP 
structure to 
interact 
directly with 
Figure 8 Known pharmacophoric model for HDAC inhibitors. EIG is the Zn binding 
group, the most useful groups are hydroxamic acid, trifluoromethyl ketone and 2-
aminoanilides. X stays for electronegative group able to do H bonding, between X and 
EIG it needs to have a CU, a idrophobic unit of connection. CAP must to be a large 
idrophobic group, such as substituted benzene rings, pyridine, pyridylmethyl groups.  
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9 1. HDACs, the big family 
TSA are completely conserved among all of the HDACs, but there is less conservation in the 
surrounding residues, with significant differences apparent between the class I and class II HDACs 30. 
Notably, there is a striking divergence in the region of Tyr91 of HDLP, and this tyrosine residue itself 
is very poorly conserved among the human HDACs. This is particularly interesting in that Tyr91 is 
positioned on the rim of the channel and interacts directly with the cap group of TSA, and it is the 
only residue that shifts its conformation upon TSA binding 29. Thus, the considerably diversity in the 
region of the protein suggests that it would be possible to develop more potent and/or specific 
inhibitors by altering the structure of this cap group. 
From the TSA/HDLP complex data, it has been possible to elaborate a structural model (common 
pharmacophore) 
for class I/II 
HDAC 
inhibition.  
This 
pharmacophore 
(figure 8) 
consists of a 
metal binding 
domain, which 
interacts with the 
active site, a 
linker domain, 
which occupies 
the channel, and 
Figure 9 HDAC 
inhibitors in clinical 
trials as anticancer 
agents. 
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10 1. HDACs, the big family 
a surface recognition domain, which interacts with residues on the rim of the active site. 
In all known natural or synthetic inhibitors it is possible to see an extremely variable cap group. This 
moiety contacts residues on the rim of the catalytic pocket and is generally connected to an 
electronegative group (connection unit, CU) that is able to interact by hydrogen bond with other 
residues. Such CU portion is bound to an hydrocarbon linker interacting with the channel residues of 
the active site of the enzyme and finishing with the enzyme inhibiting group (EIG), that in many 
cases chelate the zinc cation near the bottom of the catalytic pocket. The cap groups can be, for 
example, represented by substituted benzene rings, pyridine, pyridylmethyl groups, a portion of 
tricyclic systems or of cyclic tetrapeptides. The electronegative group is generally a ketone, an amide, 
a reverse amide, a carbamate, or a sulfonamide. The linker is a saturated or unsaturated aliphatic 
chain, which mimics that of the lysine substrate, with an optimal length of 4-6 carbon residues. In 
some cases, it is possible to find an aromatic or heteroaromatic ring inserted into the hydrocarbon 
chain. 
To date, the most useful EIG is the hydroxamic acid moiety but also ethyl ketone, trifluoromethyl 
ketone, α-ketoamide, 2-aminoanilide, thiol and its acetyl derivative (which in vivo is rapidly 
hydrolyzed) are effectively able to chelate the zinc ion. 
The epoxyketone and epoxy groups of some natural inhibitors seem to react irreversibly with some 
nucleophilic residues of the catalytic pocket of the HDAC enzymes, but the ketone group can also 
interact in its hydrate form as ligand with the metal ion. In the last ten years, a number of HDAC 
inhibitors have been reported as useful tools for the study of function of chromatin acetylation and 
deacetylation, and gene expression. These compounds can be natural or synthetic. 
Since the discovery that the antileukemia properties of trichostatin A (TSA) are due to inhibition of 
HDAC enzymes, a large number of structurally different HDACi have been reported as novel 
antiproliferative and cytodifferentiating agents. In addition to vorinostat and romidepsin, valproic 
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acid (VPA), panobinostat (LBH589), belinostat (PDX101), givinostat (ITF2357), entinostat (MS-
275), and mocetinostat (MGCD0103) (Figure 9) are into Phase II/III clinical trials for the therapy of 
hematological disorders as well as solid tumors 31. 
2. SIRTUINS, the “energy road” 
Sirtuins (SIRT1–7) are the mammalian homologues of the silent information regulator 2 (Sir2) first 
discovered in 
Saccharomyces 
cerevisiae as an NAD+-
dependent histone 
deacetylase (HDAC). 
They are classified as 
class III HDACs: they 
require NAD+ as a 
cofactor to exert their 
biological function. They 
contain an evolutionarily 
conserved core domain, 
which is essential for their activity as NAD+-dependent deacetylases or ADP-ribosyltransferases 32, 
33
. Sirtuin biology is complex, and sirtuins are widely expressed in normal tissues 34. They are 
involved in a myriad of cellular and tissue functions, such as regulating oxidative stress, repairing 
DNA, increasing genomic stability, and affecting cell survival, apoptosis, development, metabolism, 
aging and longevity 35, 36. Some sirtuins are located in different cellular compartments. Those in the 
same compartment, such as the mitochondrial SIRT3, 4, and 5, have different sequences and thus 
Figure 10. Proposed mechanism for sirtuin deacethylation 
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unique and diverse cellular functions and can interact with different targets 36. 
Sirtuins have gained considerable attention for their impact on mammalian physiology, since they 
may provide novel targets for treating of many diseases. 
2.1. SIRT1, a busy target 
Human SIRT1 is implicated to play a role in a number of age-related human diseases and biological 
functions including cell survival, apoptosis, stress resistance, fat storage, insulin production, glucose 
homeostasis, and lipid homeostasis through direct deacetylation or regulation of its many known in 
vivo targets including p53, Ku70/Bax, FOXO, PPARγ, PGC1α, UCP2, LXR, and NFκB 37, 38. 
As an NAD+-dependent enzyme, SIRT1 regulates gene expression programs in response to cellular 
metabolic status, thereby coordinating metabolic adaptation of the whole organism. Several important 
Table 1. Diversity of mammalian sirtuins 
Genes Dev. 2006 20: 2913-2921 1 
Journal of Medicinal Chemistry, 2011, Vol. 54, No. 2 
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mechanisms have emerged for SIRT1-dependent regulation of transcription 39. 
SIRT1 has recently been shown to attenuate amyloidogenic processing of amyloid-β protein 
precursor (APP) in cell culture studies in vitro and in transgenic mouse models of Alzheimer's disease 
by increasing α-secretase production and activity through activation of the α-secretase gene 
ADAM10. Because α-secretase is the enzyme responsible for the non-amyloidogenic cleavage of 
APP, upregulation of α-secretase shifts APP processing to reduce the pathological accumulation of 
the presumptive toxic Aβ species that results from β-secretase and γ-secretase activity. Therapeutic 
upregulation of SIRT1 might provide opportunities for the amelioration of Alzheimer's-disease-type 
neuropathology through inhibition of amyloidogenesi 40. 
In vasculature of rodent models, SIRT1 mediates vasodilatation via eNOS-derived nitric oxide (NO) 
and scavenging reactive oxygen species (ROS). Recent studies demonstrated further protective roles 
of SIRT1 in vascular biology and atherosclerosis. 
In endothelial cells and macrophages, SIRT1 has anti-inflammatory functions by downregulating the 
expression of various pro-inflammatory cytokines by interfering with the NF-kB signaling pathway 
41
.  
2.2. The “handy-enzyme” SIRT2 and the emergent SIRT3 
SIRT2 is involved in multiple biological functions, including affecting cell mitosis, cell motility and 
oligodendrocyte differentiation 42, 43, 44, 45. There are also studies suggesting that SIRT2 may play 
either detrimental or beneficial roles on cell survival. Several studies have suggested that SIRT2 
activation can reduce cell survival under certain conditions. For example, SIRT2 activation induces 
increased expression of Bid thus leading to apoptosis 46; and SIRT2 inhibition reduces α-Synuclein-
induced neurotoxicity in cellular and Drosophila models of Parkinson's disease 47. However, SIRT2 
may play beneficial roles under certain conditions. 
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The effect of SIRT2 on FOXO3a could produce cytoprotective effects by inducing increased 
expression of antioxidantion enzymes such as Mn-SOD 46, and SIRT2 reductions have been shown to 
induce cell apoptosis by affecting the levels of p53 48. SIRT2 has also been shown to be severe ly 
reduced in a number of human brain tumor cell lines, which implicates that the absence of SIRT2 
may mediate cellular transformation and development of cellular malignancy 49, 50. 
SIRT3 was identified as a stress responsive deacetylase recently shown to play a role in protecting 
cells under stress conditions 51.  
2.3. SIRT modulators 
Several groups have published on SIRTs inhibitors and activators. Such agents could offer important 
clues to the 
specific role 
of each 
isoform in 
biological and 
disease 
mechanisms. 
While the 
preponderanc
e of genetic 
data indicates 
that 
increasing 
SIRTs levels 
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or their activity has beneficial physiological effects, reports are sometimes conflicting.  
2.3.1 SIRT activators 
Resveratrol is a natural compound studied in 2003 52 as first sirtuin activator. In the last years other 
sirtuin activators are been reported 53, 54, 55.  
2.3.2 SIRT inhibitors 
Sirtuins may play a critical role in tumor initiation, progression, and drug resistance as well, by 
blocking 
senescen
ce and 
apoptosis
, and 
promotin
g cell 
growth 
and 
angiogen
esis. 
SIRT 
inhibitors 
have 
shown 
promisinFigure 12. Known SIRT inihibitors 
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g anticancer effects in animal models of cancer 56.  
A large number of themhave been identified such as sirtinol 57, splitomycin 58, cambinol 59, tenovin 60, 
Ro-318220 61, surfactin 62, suramin 63, the potent SIRT1 inhibitor indole EX527 64 analogs and the 
SIRT2 inhibitor AGK2 47. 
3. HDMs, the histone demethylases  
Histone methylation plays a very special role in specifying the various chromatin states. The recent 
discovery of histone demethylases, which represent a large family of enzymes often containing 
histone modification binding modules, sheds new light on cross-talk mechanisms involving 
methylated residues. Studies exploring the histone demethylases JmjC (Jumonji C domain)–
containing proteins65, and histone lysine demethylases FAD dependent LSD1-2 66, 67, primarily 
identified their enzymatic activity at the promoters of specific target genes and in general increased 
the knowledge about the several pathways where they are involved 68, 69, 70. 
3.1 LSD1 and LSD2 
LSD1 acts on mono- and dimethylated H3K4 through a flavin-dependent mechanism (Figure 13) 
according to the following reaction: 
H3-Lys4-CH3 + O2 + H2O               H3-Lys4 + H2O2 + HCHO 
Figure13. LSD1-2 enzymatic mechanism (Genes Dev. 2008 22: 1115-1140) 
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H3K4 methylation is a gene activation marker 71, and LSD1 was originally identified as a component 
of transcriptional repressor complexes 72, 73. LSD1 is typically associated with a transcriptional 
corepressor protein (CoREST) and histone deacetylase (HDAC) 1 or 2, forming a stable core 
subcomplex recruited by many chromatin remodeling multiprotein complexes 72, 74. However, LSD1 
is also involved in some gene activation processes, thus highlighting its multifaceted function in 
chromatin regulation 75, 76. It participates in several growth-promoting pathways, and its levels are 
upregulated in certain high-risk tumors 77, 78. The potential link between cancer and LSD1 activity is 
underpinned by the fact that loss of H3K4 methylation and enrichment of H3K9 methylation are 
associated with several types of tumors 79. 
Recently Mattevi et al. reported the discovering of a second mammalian flavin-dependent histone 
demethylase, named LSD2 67. The new demethylase is strictly specific for mono- and dimethylated 
Lys4 of histone H3, recognizes a long stretch of the H3 N-terminal tail, senses the presence of 
additional epigenetic marks on the histone substrate, and is covalently inhibited by tranylcypromine. 
As opposed to LSD1, LSD2 does not form a biochemically stable complex with the C-terminal 
domain of the corepressor protein CoREST. Furthermore, LSD2 contains a CW-type zinc finger 
motif with potential zinc-binding sites that are not present in LSD1. 
The functions and mechanisms of several LSD1/KDM1a family histone demethylases have been 
intensively 
studied in 
multiple 
model 
organisms, 
including 
human, 
Figure 14. Schematic representations of LSD2 and LSD1. ZF, zinc finger domain; SW, 
SWIRM domain; AO, amine oxidase domain; F, FAD-binding motif; L, linker 80. 
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mouse, Drosophila, C. elegans, and S. pombe. Yet our knowledge of the precise roles of LSD1 family 
members remains mostly limited to promoter association and regulation. Specifically, one key 
function of LSD1 is balancing promoter H3K4/H3K9 methylation for activation or repression of 
LSD1 target genes.  
LSD2/KDM1b/AOF1, the only mammalian homolog of LSD1, specifically associates with the 
coding region of its target genes. LSD2 shares similar substrate specificity with LSD1 and 
demethylates mono-and dimethylated H3K4. Instead of functioning as a corepressor, LSD2 is 
important for optimal gene transcription. LSD2 is unique in associating specifically with the gene 
bodies of actively transcribed genes, but not at promoters. A specific function of LSD2 is to maintain 
low levels of H3K4 methylation within elongation regions. Furthermore, LSD2 forms complexes 
with H3K9 and H3K36 methyltransferases. These enzymes together orchestrate appropriate histone 
modifications in order to maintain a repressive chromatin structure at elongation regions, which may 
be important for optimal transcription elongation 80. 
What until recently seemed to be a puzzle with a few pieces, day by day is becoming more complex 
and complete. 
While increasing 
the information 
about functions 
and targets of all 
these epigenetic 
enzymes, new 
elegant and 
exiting cellular 
epigenetic 
Figure 15. Model of gene transcription regulation by LSD2 complex. LSD2 localizes to 
the 30 end of actively transcribed genes, where it can interact with phosphorylated RNA 
Pol II and elongation factors. The LSD2 complex coordinates intragenic H3K4me2 and 
H3K9 methylation and potentially H3K36me2 levels via its own intrinsic demethylase 
activity and through interaction with histone methyltransferases G9a and NSD3 80. 
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mechanisms are discovering.  
3.1.1 Biological role of LSD1: HOTAIR interaction. 
Long intergenic noncoding RNAs (lincRNAs) regulate chromatin states and epigenetic inheritance. 
The lincRNA HOTAIR serves as a scaffold for at least two distinct histone modification complexes. 
A 5′ domain of HOTAIR binds Polycomb Repressive Complex 2 (PRC2) 
while a 3′ domain of HOTAIR binds the LSD1/CoREST/REST complex. The ability to tether two 
distinct complexes enables RNA-mediated assembly of PRC2 and LSD1, and coordinates targeting of 
PRC2 and LSD1 to chromatin for coupled histone H3 lysine 27 methylation and lysine 4 
demethylation. The results of recent study made by R.A. Miao-Chih Tsai et Al., suggest that 
lincRNAs may serve as scaffolds by providing binding surfaces to assemble select histone 
modification enzymes, and thereby specify the pattern of histone modifications on target genes. The 
lincRNA termed HOTAIR is increased in expression in primary breast tumours and metastases, and 
HOTAIR expression level in primary tumours is a powerful predictor of eventual metastasis and 
death. Using a series of HOTAIR deletion mutants, they showed that HOTAIR is a modular   
bifunctional RNA 
that has distinct 
binding domains for 
PRC2 and LSD1 
complexes. 
HOTAIR-mediated 
bridging of PRC2 
and LSD1 
complexes also Figure 16. HOTAIR interaction with LSD1,  
Nat Biotechnol. 2010 Sep;28(9):931-2 
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enables their coordinate binding to target genes on chromatin. These findings indicate that this 
lincRNA has active roles in modulating the cancer epigenome by working with LSD1, the important 
conseguence is that both of them may be important targets for cancer diagnosis and therapy 81. 
3.1.2 Biological role of LSD1: BLIMP-1 interaction. 
Plasma cell differentiation is orchestrated by the transcriptional repressor B lymphocyte-induced 
maturation protein-1 (Blimp-1), which silences the gene expression program of mature B cells. The 
molecular mechanism underlying Blimp-1 suppression of mature B-cell gene expression is not fully 
understood but it is known that the mechanism underlying Blimp-1-mediated gene suppression, at 
least partially, includes interaction with several proteins, including HDAC1/2 82, Groucho family 
proteins 83, and G9a histone methyltransferase 84. Blimp-1 also interacts with the histone arginine 
methyltransferase, Prmt-5, during germ cell development 85 and with LSD1 for the repression of the 
mature B-cell gene expression program. Recently Shin-Tang Su at al., report that a proline-rich 
domain in Blimp-1 directly interacts with LSD1. Both LSD1 knockdown and expression of Blimp-1 
lacking the proline-rich domain derepressed the activities of Blimp-1-dependent luciferase reporters. 
Disruption of the Blimp-1 interaction with LSD1 or reduced LSD1 expression attenuated antibody 
production, demonstrating the biological significance of this interaction. Finally, using chromatin 
immunoprecipitation, they showed that Blimp-1 binding to its target sites is accompanied by LSD1 
binding to those same sites and that LSD1 binding correlates with histone modifications of accessible 
chromatin 86. This new finding is a very usefull information to understand better the LSD1 dependent 
pathways and clarify all the mechanism involved. 
3.1.3 Biological role of LSD1: SNAIL-1 interaction 
Epithelial–mesenchymal transition (EMT) is a transdifferentiation programs that is required for tissue 
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 morphogenesis during embryonic development. The EMT process can be regulated by a diverse 
array of cytokines and growth factors, such as transforming growth factor (TGF)-β, whose activities 
are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in 
the acquisition of invasive and metastatic properties. The mechanism underlying the epigenetic 
regulation of EMT remains unclear.  
At the present, we know that a hallmark of EMT is the loss of E-cadherin, expression, which is often 
inversely correlated with tumour grade and stage. E-cadherin is a single-span transmembrane 
Figure 17. Model of the regulatory mechanisms modulating Snail1 stability and activity.  
The EMBO Journal (2010) 29, 1787–1789 
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glycoprotein that maintains intercellular contacts and cellular polarity in epithelial tissues, its loss is 
associated with tumor invasiveness, metastatic dissemination, and poor prognosis in several solid 
tumors 87, 88. Down-regulation of E-cadherin is believed to induce epithelial-mesenchymal transition 
(EMT) 89 characterized by dedifferentiation of neoplastic epithelial cells to a more motile 
mesenchymal phenotype. Several transcription factors, such as Snail-1, Twist and ZEB1, have been 
implicated in the transcriptional repression of E-cadherin, in the induction of EMT and consequently 
in the cancer metastasis. In 2009 J. Von Burstin et al.’s work demonstred that E-Cadherin is 
suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex linking the epigenetic HDAC 
machinery to EMT and metastasis 90. 
In 2011 Y. Lin et al. showed that Snail-1, known clearly involved in EMT and correlated with high 
tumour grade and nodal metastasis, interacted with histone lysine-specific demethylase 1 (LSD1) 91. 
They demonstrated that LSD1 is able to interact with the Snail-1 amino terminal sequence, named 
SNAG, using the amine oxidase domain. Interestingly, the sequence of the SNAG domain is similar 
to that of the histone H3 tail, and the interaction of Snail1 with LSD1 can be blocked by LSD1 
enzymatic inhibitors and a histone H3 peptide. So apparently, the SNAG domain of Snail1 resembles 
a histone H3-like structure, functions as a molecular hook for recruiting LSD1 to its target gene 
promoters, and resulted in suppression of cell migration and invasion 92. 
The knowledge about this kind of epigenetic control on tumor grade becames at the present a new 
exiting information to use with the objective to find a real able method for checking and blocking the 
tumor progression and the metastases onset. 
3.2 LSD1-2 inhibitors 
Within the framework of the so-called epigenetic therapies, there is a growing interest in these 
enzymes as a potential drug target. 
Since LSD1 and MAO-A/B share a common mechanism for the oxidative cleavage of the unactivated 
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nitrogen-carbon bonds of their substrates, many of the known MAO inactivators have been tested as 
LSD1 inhibitors93, Tranylcypromine displayed the best activity with an IC50 of less than 2 µM. Since 
this first study a lot of groups started to work on design and synthesis of new LSD1 inhibitors as  
tranylcypromine derivatives getting in some cases very nice results 94 , 95, 96, 97, 98 (Figure 18). 
The AO domain of LSD1 shares 20% sequence similarity with those of the FAD-dependent MAO 
and PAO (polyamine oxidases such as spermine oxidase [SMO] and N1-acetylpolyamine oxidase), 
with the catalytic domains of LSD1 and SMO showing 60% similarity in amino acid sequences. As 
compounds bearing guanidine groups were shown to inhibit both SMO and other polyamine 
Figure 18. Known LSD1 inhibitors  
*tranylcypromine showed different Ki value in different reported studies. 
Genes & Cancer 2011, (6) 663–679. 
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oxidases, a pioneer series of (bis)guanidines and (bis)biguanides were tested as inhibitors of LSD1 99. 
Afterwards newer and more powerful polyamine analogues designed showing the importance of this 
different molecular scaffold in design LSD1 inhibitors 100, 101.  
4. New frontiers in Epigenetics 
As I have underlined above, the chromatine remodeling is an important epigenetic control of gene 
expression. Many studies reported the existence of syndromes of disordered “chromatin remodeling” 
as general deregulation of DNA transcription caused by mutations in genes encoding enzymes which 
mediate changes in chromatin structure. These mutations result in a loss of proper regulation of 
chromatin structure, which in turn causes deregulation of gene transcription and inappropriate protein 
expression. Some of the genetic diseases that arise because of disordered chromatin remodeling 
include: Alpha-Thalassemia/Mental Retardation Syndrome, ATR-X (ATM/Rad3-related); Rett 
Syndrome (RS); ICF (Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome); 
RSTS (Rubinstein-Taybi Syndrome), and CLS (Coffin-Lowry Syndrome) 102. Recently M.E. Pennini 
et al. demonstrate the ability of the Mycobacterium tubercolosis (Mtb) 19-kDa   lipoprotein, a TLR2 
agonist expressed by virulent Mtb, to inhibit IFN-γ-induced histone acetylation at one locus 
(MHC2TA), but not another (NOS2). However, the mechanism for targeted inhibition of a subset of 
IFN-γ-dependent genes is still uncertain, but the proposed mechanism implicates the  regulation of 
chromatin remodeling as a mechanism for Mtb-mediated inhibition of CIITA expression The 
causative bacterium in humans is Mycobacterium tuberculosis, although infection is necessary, it is 
not sufficient to cause tuberculosis in most people, human factors governing whether the infected 
individual will progress to active tuberculosis disease or not are usually assumed to be those 
governing the immunological state of the host, which are generally determined by the host’s genetic 
make-up. Even the effects of stress and nutrition on the immune response can be influenced by 
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genetics and epigenetic mechanisms of gene regulation 103. 
Epigenetic mechanisms, such as aberrant DNA methylation and histone acetylation, regulate the 
transcription rate and/or tissue-specific expression of certain genes without altering the primary 
nucleotide sequence of the DNA. DNA methylation plays an important role in the arrangement of 
some key biological activities such as imprinting and silencing of chromosomal domains 104,105. It 
occurs at the cytosine residue in the context of a CpG dinucleotide and in the promoter regions, where 
it can act as an important modifier of transcription. The relationship between the methylation of the 
CpG islands and gene expression is very complex and some reports suggest that the change of 
methylation intensity of the promoter CpG islands is negatively correlated with gene expression 
levels 106, 107. Histone acetylation is crucial for gene transcription. Histone acetylation sites and 
histone acetyltranferases are required for chromatin folding and gene activity, as opening of the 
chromatin conformation allows binding of transcription factors. Similarly, histone deacetylation plays 
an important role in transcription 108. It was found that signalling by M. tuberculosis, or its 19-kDa 
lipoprotein, inhibited IFN-γ-induced class II transactivator (CIITA) expression and this process was 
linked to histone deacetylation at the CIITA gene 109. Acetylation may therefore contribute to 
tuberculosis susceptibility. It has been shown that M. tuberculosis may interfere with epigenetic 
regulation; therefore, it is possible that these epigenetic mechanisms may be found to play a role in 
host susceptibility to tuberculosis. 
4.1. Introduction and biological activity of Rufomycin B 
The rufomycin B (figure 20) is an antibiotic isolated from Streptomyces atratus in 1962 by Higashide 
et al., it is neutral, lipophylic polypeptide antibiotic composed of seven L-amino acids; L-alanine, L-
N-methyl-leucine (2 moles), L-3-nitrotyrosine, L-leucine, L-2-amino-4-hexenoic acid and L-N-(2-
methyl-3-buten-2-yl)- tryptophan as shown in figure 20. Biological tests showed that Rufomycin B is 
inactive against Gram positive and negative bacteria, fungi, and yeast examined, though it has a high 
 PhD course in Pasteurian Sciences, XXIV cicle, Rome, 29th February, 2012 
 
27 4. New frontiers in Epigenetics 
antibiotic activity against acid-fast bacteria, especially 
Mycobacterium tuberculosis H37Rv which have been 
rendered resistant to one or two of the following 
substances: streptomycin, neomycin, kanamycin and 
isonicotinic acid hydrazide (table 2) 110. Tuberculosis is 
one of the most influential diseases in the history of 
mankind due to its devastating effect on health and its 
high mortality rate throughout the world. The World 
Health Organization (WHO) has estimated that 2 billion 
people 
have 
latent TB 
and that 
globally, 
in 2009, 
the 
disease 
killed 1.7 
million 
people 
111
. 
 New 
TB 
treatment
s are >100Candida albicans5.0
Mycobact. Avium (SM-
resistant)
>100Pen. crysogenum5.0Mycobact. avium
>100Sacc. cerevisiae5.0Mycobact.607
1.0Mycobact. Tuber. H37Rv (INHA-
resistant)>100Sarcina lutea
2.0Mycobact. Tuber. H37Rv (SM-KM 
resistant)>100Bacillus brevis
2.0Mycobact. Tuber. H37Rv (KM- resistan)>100Bacillus subtilis
2.0Mycobact. Tuber. H37Rv (SM-resistant)>100Staphylococcus aureus
1~5.0Mycobact. Tuber. H37Rv>100Serratia marcescens
5.0Mycobact. Phlei>100Pseudomonas aeruginosa
0.5Mycobact.smegmatis>100Proteus vulharis
5.0Mycobact. Avium (NM-resistant)>100Escherichia coli
MIC γ/mlTest organismMIC 
γ/mlTest organism
TABLE 1.    Antibacterical spectrum of Rufomycin BTable 2. antibacterical spectrum of Ru omycin B 
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being developed 112, and new TB vaccines are under investigation 113. 
Although TB rates are decreasing in the United States, the disease is becoming more common in 
many parts of the world. In addition, the prevalence of drug-resistant TB is also increasing 
worldwide. Co-infection with the human immunodeficiency virus (HIV) has been an important factor 
in the emergence and spread of resistance. Since its discovery, no one total synthesis of Rufomycin B 
has been reported in literature. Since many years, the Ely Lilly company is studying this peptidic 
scaffold in order to get new compounds which are useful as antibiotics, reporting a fermentative 
synthesis 114. 
5. New cynnammil containing HDAC inhibitors  
As I told before, the pharmacophore model for HDACi includes a cap group (CAP) that interacts with 
the rim of the catalytic tunnel of the enzyme, a polar connection unit (CU) linked to a hydrophobic 
spacer (HS) which allows the molecule to lie into the tunnel, and a Zn-binding group (ZBG) able to 
complex the Zn+2 at the bottom of the cavity 114, 115. Besides TSA and SAHA, the two prototypes of 
natural and synthetic HDACi, which present an aliphatic chain as HS, a number of HDACi carrying 
the cinnamyl moiety as HS has been described so far, starting from the SAHA related hybrid polar 
compound cinnamyl bishydroxamic acid (CBHA) 116-123. Among them, HDAC42 124 was described as 
a novel phenylbutyrate-based HDACi highly active in prostate cancer, in hepatocellular carcinoma, in 
ovarian cancer, and able to sensitize prostate cancer cells to DNA-damaging agents through Ku70 
acetylation 125-129. Moreover, the cited belinostat and panobinostat (Figure 21) are two examples of 
cinnamyl-containing HDACi at the present in clinical trials for the treatment of many forms of 
tumors 130, 131. Mai et al., worked on design, synthesis, and biological evaluation of HDACi with 
some aroyl-pyrrolylhydroxamates (APHAs), characterized by an aroyl portion as CAP+CU, a 
pyrrylacrylic moiety as HS, and the hydroxamate group as ZBG 132-137. Afterwards, by replacing the 
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pyrrole nucleus with the benzene ring, they are been reported two different series of cinnamyl 
hydroxamates, the N-hydroxy-3-(2-, 3-, and 4-aroylaminophenyl)acrylamides138 and the N-hydroxy-
3-(4-(3-oxo- 3-phenylprop-1-enyl)phenyl)acrylamides 139, 140, acting as anticancer agents through 
HDAC inhibition. Following these searches on cinnamyl compounds, I worked on the synthesis and 
enzyme and in-cell evaluation of new arylacetylamino- and arylmethylamino-cinnamyl hydroxamates 
and 2-aminoanilides (1-4), tested as HDACi and pro-apoptotic, antiproliferative, and/or 
cytodifferentiating agents.  
In particular, choosing a cinnamyl moiety as a HS, I inserted some arylacetylamino portions carrying 
Figure 21. Cinnamyl-containing HDACi 
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an alkyl/aryl/arylalkyl substituent at the methylene group (compounds 1 and 2), or alternatively a 
wide range of (hetero)arylmethylamino groups (compounds 3 and 4) (CAP+CU groups). All the 
arylacetylamino- and arylmethylaminocinnamyl compounds were prepared both as hydroxamates (1 
and 3) and 2-aminoanilides (2 and 4) (ZBGs: -CONHOH or – CONH(2-NH2)Ph). In order to get the 
biological evaluations, all the new compounds were screened against human HDAC1 and maize 
HD1-B (class I HDACs), and human HDAC4 and maize HD1-A (class IIa HDACs), to assess their 
inhibitory activities and selectivity, and in human leukemia U937 cells in order to:  
• verify their capability to increase the acetylation levels of histone H3 and α–tubulin,  
•  induce the tumor suppressor protein p21WAF1/CIP1. 
• test the effects on cycle cell, the induction of apoptosis, the inhibition of proliferation , and 
the granulocytic differentiation  
 SAHA, MS-275, and HDAC42 were prepared and included in the assays as reference drugs. 
5.1. Chemistry 
The title compounds were prepared starting from the key intermediate ethyl 4-aminocinnamate 
hydrochloride 138, that was treated with the properly substituted arylacetyl chlorides in the presence of 
triethylamine to afford the ethyl 3-(4-(2- arylacetamido)phenyl)acrylates 5a-n. Alternatively, the 
ethyl 4-aminocinnamate hydrochloride was condensed with the appropriate aldehydes to obtain the 
aldimine intermediates that were reduced to the ethyl 3-(4-(arylmethylamino)phenyl)acrylates 7a-o 
with sodium cyanoborohydride. The ethyl esters 5 and 7were hydrolyzed in basic medium to the 
related acrylic acids 6 and 8, respectively. Further reaction of these 3-(4-(2- arylacetamido)- or 3-(4- 
(arylmethylamino)phenyl)acrylic acids (6a-n or 8a-o, respectively) with i) ethyl chloroformate and 
triethylamine, ii) O-(2-methoxy-2- propyl)hydroxylamine 141, and iii) Amberlyst 15 ion-exchange 
resin in methanol furnished the hydroxamates 1a-n (from 6) or 3a-o (from 8). Alternative treatment 
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of 6a-l or 8a-o with benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate 
Scheme 1 : a) RCOCl, Et3N, dry CH2Cl2, 0 °C to rt; b) LiOH, THF/H2O, rt; c) 1) ClCOOEt, Et3N, dry THF, 0 °C; 2) 
CH3OC(CH3)2ONH2, dry THF, 0 °C; 3) Amberlyst 15, MeOH, rt; d) 1) Et3N, BOP reagent, dry DMF, N2; 2) 1,2-
phenylendiamine, dry DMF, N2; e) 1) R1CHO, CH3COOH, MeOH, rt; 2) NaCNBH3, MeOH, rt. f: 2 N KOH, EtOH, 
rt. 
Scheme 2. R and R1 substituents used as acyl chloride (R) and aromathic aldehide (R1) 
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(BOP-reagent), triethylamine and 1,2-phenylendiamine afforded the corresponding 2-aminoanilides 
2a-l or 4a-o, respectively (Scheme 1). 
Table 3. Chemical and Physical Data for Compounds 1-4[a] 
cpd mp, °C recryst 
solvent[b] yield, % cpd mp, °C 
recryst 
solvent[b] yield, % 
1b 133-135 A 67.3 3d 216-218 C 88.7 
1c 128-130 A 59.8 3e 152-154 B 78.5 
1d 146-148 B 68.4 3f 162-164 B 58.3 
1e 146-148 B 54.9 3g 196-198 C 76.8 
1f 110-112 A 67.6 3h 150-152 B 79.1 
1g 238-240 E 58.3 3i 216-218 C 68.4 
1h 182-184 B 61.3 3j 198-200 C 61.3 
1i 216-218 C 59.2 3k 226-228 C 76.4 
1j 108-110 A 65.7 3l >250 E 75.6 
1k 160-162 B 75.6 3m 216-218 D 67.6 
1l 160-162 B 77.8 3n 170-172 B 75.9 
1m 130-132 A 75.9 3o 135-137 A 80.9 
1n 103-105 A 76.8 4a 172-174 B 87.0 
2a >250 E 55.2 4b 170-172 B 78.5 
2b 228-230 C 87.0 4c 248-250 E 75.7 
2c 200-202 C 78.5 4d 186-188 B 77.5 
2d 180-182 B 75.7 4e 178-180 B 59.2 
2e 239-241 E 74.6 4f 190-192 B 72.8 
2f 240-242 E 72.8 4g 156-158 B 73.9 
2g >250 E 77.4 4h 180-182 A 67.9 
2h 244-246 E 78.5 4i 180-182 B 65.7 
2i 248-250 E 76.4 4j 198-200 C 77.4 
2j >250 E 78.9 4k 208-210 C 78.9 
2k 206-208 E 80.9 4l 222-224 E 77.8 
2l 206-208 E 81.1 4m 232-234 E 74.6 
3a 184-186 D 67.3 4n 210-212 C 76.8 
3b 148-150 B 59.8 4o 192-194 C 81.1 
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Chemical and physical data of the tested compounds 1-4 (except 1a) and the intermediates 5-8 
(except 5a and 6a) are reported in Table 3 and 4. 
3c >250 E 54.9     
[a] Analytic results were within ±0.40% of the theoretical values. [b] A, benzene; B, 
benzene/acetonitrile; C, acetonitrile/methanol; D, acetonitrile; E, methanol. 
Table 4. Chemical and Physical Data for Compounds 5-8[a] 
cpd mp, °C recryst 
solvent[b] yield, % cpd mp, °C 
recryst 
solvent[b] yield, % 
5b 114-116 A 87.3 7c 118-120 B 63.1 
5c 109-111 A 88.2 7d 130-132 B 90.0 
5d 133-135 B 78.4 7e 118-120 B 73.8 
5e 95-97 A 78.7 7f 114-116 B 67.8 
5f 114-116 A 83.6 7g 66-68 A 58.4 
5g 151-153 C 77.5 7h 96-98 A 63.5 
5h 143-145 B 73.4 7i 134-136 B 74.6 
5i 144-146 B 83.4 7j 111-112 B 77.3 
5j 200-202 C 85.0 7k 102-104 A 79.6 
5k 135-137 B 81.1 7l 138-140 B 68.9 
5l 125-127 B 79.0 7m 204-206 C 81.3 
5m 105-107 A 82.2 7n 102-104 A 55.3 
5n 144-146 C 82.2 7o 106-108 A 61.7 
6b 224-226 D 94.5 8a 180-182 F 88.6 
6c 202-204 D 88.6 8b 148-150 C 85.4 
6d 198-200 C 95.7 8c >250 E 95.3 
6e 162-164 C 85.7 8d 156-158 C 95.3 
6f 171-173 C 89.0 8e 186-188 F 85.6 
6g >250 E 82.3 8f 184-186 F 89.8 
6h 168-170 C 81.0 8g 158-160 C 91.6 
6i >250 E 83.4 8h 190-192 F 92.2 
6j >250 E 86.7 8i 198-200 F 91.9 
6k 186-188 C 85.3 8j >250 E 87.1 
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Table 5. Maize HD1-B and HD1-A Inhibitory Activity 
of Hydroxamate Compounds 1 and 3 
compd IC50 ± SD (µM) HD1-B HD1-A 
1a 0.092 ± 0.003 0.072 ± 0.004 
1b 0.072 ± 0.003 0.080 ± 0.003 
1c 0.089 ± 0.004 0.064 ± 0.002 
1d 0.083 ± 0.003 0.140 ± 0.007 
1e 0.187 ± 0.006 0.057 ± 0.002 
1f 0.126 ± 0.005 0.057 ± 0.003 
1g 0.162 ± 0.006 0.055 ± 0.003 
1h 0.133 ± 0.004 0.074 ± 0.003 
1i 0.011 ± 0.0005 0.015 ± 0.001 
1j 0.032 ± 0.001 0.056 ± 0.003 
1k 0.058 ± 0.002 0.042 ± 0.001 
1l 0.062 ± 0.002 0.069 ± 0.003 
1m 0.065 ± 0.002 0.196 ± 0.010 
1n 0.064 ± 0.003 0.132 ± 0.005 
3a 0.020 ± 0.001 0.102 ± 0.003 
3b 0.058 ± 0.002 0.154 ± 0.005 
3c 0.690 ± 0.021 0.160 ± 0.005 
3d 0.150 ± 0.007 0.112 ± 0.003 
3e 0.025 ± 0.001 0.059 ± 0.002 
3f 0.027 ± 0.001 0.072 ± 0.004 
3g 0.124 ± 0.005 0.045 ± 0.002 
3h 0.102 ± 0.005 0.098 ± 0.004 
3i 0.046 ± 0.002 0.022 ± 0.001 
3j 0.026 ± 0.002 0.020 ± 0.001 
6l 187-189 C 84.0 8k >250 E 95.2 
6m >250 E 86.5 8l >250 E 92.8 
6n >250 E 82.3 8m 204-206 D 85.8 
7a 110-115 B 70.3 8n 216-218 D 88.1 
7b 80-82 A 66.7 8o 212-214 D 89.3 
[a] Analytic results were within ±0.40% of the theoretical values. [b] A, cyclohexane; B, 
cyclohexane/benzene; C, benzene/acetonitrile; D, acetonitrile/methanol; E, methanol; F, acetonitrile.. 
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3k 0.031 ± 0.001 0.020 ± 0.001 
3l 0.700 ± 0.035 0.900 ± 0.054 
3m 0.042 ± 0.001 0.037 ± 0.002 
3n 0.118 ± 0.006 0.069 ± 0.003 
3o 0.127 ± 0.005 0.070 ± 0.004 
SAHA 0.028 ± 0.001 0.180 ± 0.009 
HDAC42 0.009 ± 0.0005 0.006 ± 0.0003 
[a] Data represent mean values of at least three separate 
experiments. 
5.2. Results and Discussion 
5.2.1. Enzyme Inhibitory Assays. Maize HD1-B and HD1-A 
Enzymes. 
Compounds 1-4 were tested against partially purified maize HD1- B and HD1-A, two homologs of 
class I and class II HDACs, respectively. The maize enzymes are not sensitive to non hydroxamate 
HDACi up to 250 µM, so just compounds 1 and 3 are tested. The best results are obtained for the 
compounds with a small alkyl group (methyl, ethyl, cyclopropyl), or its isoster (methoxy), at the 
methylene of the phenylacetyl portion, whereas the derivatives with bigger substituents at such a 
position (i.e., iso-propyl, allyl, phenyl, benzyl) were less active.  Differently, in the case of HD1-A all 
used substituents furnished inhibitory effects to the derivatives, with the exception of the methoxy 
and the cyclopropyl (1,1- as well as 1,2-disubstituted) groups, that caused a drop of the HD1-  A 
inhibitory activity of the corresponding derivatives 1d, 1m, and 1n. In regard to the arylmethylamino-
cinnamyl hydroxamates 3, the first member of the series (the 3-(4 (benzylamino)phenyl)- 
Nhydroxyacrylamide 3a displayed high and 5-fold lower potency againstHD1-A (IC50 HD1-B 
=0.020 µM; IC50 HD1-A = 0.102 µM). inhibitory activity against HD1-B. Among the (hetero)mono- 
and bicyclic rings replacing the benzene at the R1 position in 3a only the 2- thienyl, 3-thienyl, 
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2-naphthyl, and 2-benzofuryl rings assured a 
comparable inhibiting potency against HD1-
B, the other being detrimental for enzyme 
inhibition to various extent. In the anti- HD1-
A assay, in addition to the chemical 
replacements that were important for the 
HD1-B inhibition, the substitution of the 3a 
benzene ring with the 2-pyridyl, 1-naphthyl, 
3-benzothienyl, 2- and 3-quinolinyl rings 
increased up to 5-fold the HD1-A inhibitory 
activity of the compounds. The trend of 
structure-activity relationship (SAR) observed 
with 1 and 3 confirmed some our previous 
findings, according to which the requirements 
for a HDACi to inhibit maize HD1-B are 
more stringent than those to inhibit HD1-A: 
HD1-A has a larger catalytic tunnel than 
HD1-B, so it can easier accommodate a wider 
variety of chemically  different compounds. 
5.2.2. Human Recombinant 
HDAC1 and HDAC4 Assays.  
All the compounds were tested at 5 µM 
against human recombinant  (hr) HDAC1 and 
Table 6. Human Recombinant HDAC1 and 
HDAC4 Inhibitory Activity of Compounds 1 
and 2[a] 
compd   % of inhibition at 5 µM hrHDAC1 hrHDAC4 
1a 59.8 28.9 
1b 54.6 45.0 
1c 44.5 42.4 
1d 66.6 72.4 
1e 37.5 41.6 
1f 41.2 11.9 
1g 55.3 15.3 
1h 54.7 14.9 
1i 76.2 14.0 
1j 72.7 55.3 
1k 75.4 38.9 
1l 66.9 42.4 
2a 28.6 25.5 
2b 71.3 0 
2c 56.2 47.6 
2d 72.0 38.0 
2e 73.2 16.2 
2f 56.3 60.4 
2g 25.8 70.0 
2h 42.9 50.4 
2i 59.2 25.3 
2j 58.3 6.2 
2k 76.7 23.4 
2l 72.7 25.2 
HDAC42 94.0 27.2 
SAHA 93.1 63.2 
MS-275 83.4 14.6 
[a] Data represent mean values of at least three 
separate experiments. 
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HDAC4, using the histone H3 (HDAC1) or the non-histone trifluoroacetyl-lysine 143 (HDAC4) as a 
substrate, respectively.  
From these results, it is been possible to get some interesting information about Structure-Activity 
Relationship. HDAC1 inhibitory potency is improved when: 
• the phenyl ring at the R position in prototype 1a and 2a, is replaced with 1- or 2-naphthyl 
group (compounds 1i-l), 
• a substituent (particularly a methyl, methoxy, and iso-propyl group) is introduced at the 
phenyacetyl portion the 2-aminoanilide series (compounds 2),and does not change when: 
• some substituents at the methylene portion of the phenylacetylamino moiety in the 
hydroxamate prototype 1a are introduced. With respect to HDAC4 inhibition: 
• the introduction of a small (up to the iso-propyl) substituent at the methylene connecting the 
phenyl to the carbonyl group in 1a improves the potency of the derivatives 
• a large unsaturated substituent such as the allyl, phenyl, and benzyl groups (see compounds 
2f-h) in compound 2 increases the activity  
Table 7. Chromatographic analysis of the 1st (F1) and 2nd (F2) fractions collected in the 
semipreparative enantioseparation of 1b, 1c, and 2c. 
compd mobile phase A
a
 F1 F2 
 ee(%)b ORc ee(%)b ORc 
1b n-hexane-ethyl acetate-ethanol-trifluoroacetic acid 80/20/10/0.1 5 >99.0 (+) >99.0 (-) 
1c n-hexane-ethyl acetate-ethanol-trifluoroacetic acid 80/20/10/0.1 5 >99.0 (+) >99.0 (-) 
2c n-hexane-ethanol 30/70 10 >99.0 (+) >99.0 (-) 
aAmount of sample (in mg) resolved in a single semipreparative run. bEnantiomeric purity for pooled fractions 
containing the 1st (F1) and 2nd (F2) eluted enantiomers. cSign of the optical rotation on-line monitored at 365 nm 
during elution with the mobile phases reported in table and pure ethanol. 
Column: Chiralpak IA (250 10 mm I.D.); flow-rate: 4.0 mL/min; detector: UV at 340 nm; temperature: 25 °C. 
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• the replacement of the benzene ring of 1a with the naphthyl moiety (compounds 1i-l)  
typically furnishes an 
increase in the HDAC4 
inhibiting potency, with the 
exception of compound 1i, 
that showes lower activity. 
Since with the insertion of a 
substituent at the methylene position 
of the phenylacetyl moiety of 1a and 
2a a chiral center was generated, we 
checked if in these two series of 
HDACi there is stereoselectivity of 
action.  
Single enantioners of hydroxamates 
1b and 1c, as well as the 2-
aminoanilide 2c were obtained by 
enantioselective HPLC of racemic 
forms on the amylose-based 
Chiralpak IA chiral stationary phases 
(CSP) using normal-phase conditions 
(Table 7).The absolute configuration 
assignment was accomplished by a combined strategy based on chemical correlation/chiral 
HPLC/circular dichroism (CD) methods. (R) and (S) enantiomers of 2- phenylbutyric acid were used 
as chiral synthones to obtain non racemic forms (ee >62%) of 1c and 2c. The synthesis occurred in 
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Figure 22. CD spectra of the enantiomers of 1b and 1c in 
ethanol 
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Table 8. Human Recombinant HDAC1 and 
HDAC4 Inhibitory Activity of Compounds 3 and 
4[a] 
cpd 
% of inhibition at 5 µM 
hr 
HDAC1 
hr 
HDAC4 
3a 55.6 37.5 
3b 34.6 29.1 
3c 31.9 0 
3d 48.1 0 
3e 91.5 35.2 
3f 91.5 11.1 
3g 60.6 0 
3h 60.1 30.9 
3i 45.5 49.6 
3j 94.4 22.3 
3k 74.2 0 
3l 26.0 0 
3m 69.9 0 
3n 64.9 0 
3o 52.0 0 
4a 69.4 0 
4b 42.5 0 
4c 67.7 31.9 
4d 36.7 27.3 
4e 38.5 22.9 
4f 44.4 32.4 
4g 73.2 41.0 
4h 52.3 41.9 
4i 37.5 0 
4j 51.8 0 
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4k 58.3 0 
4l 45.3 0 
4m 50.6 20.0 
4n 59.0 19.7 
4o 74.0 3.5 
SAHA 93.1 63.2 
MS-275 83.4 14.6 
[a] Data represent mean values of at least three separate 
experiments. 
stereoconservative way and the final products maintained the original absolute configuration of 
starting material.Enantioselective HPLC analysis of racemic samples spiked with the optically active  
forms of knownabsolute configuration allowed the stereochemical characterization of 1c and 2c. The 
stereochemistry of 1b was empirically achieved by comparing its CD spectra with those of the 
structurally analogue 1c(Figure 21).The enantiomers of 1b, 1c and 2c, separated on semipreparative 
scale, were tested against maize HD1-B and HD1-A, as well as against hrHDAC1 and hrHDAC4, in 
comparison with their corresponding racemates. In general, the (R)-enantiomer is slightly more active 
than the (S)-enantiomer. In the case of the two hydroxamates 1b and 1c, the inhibition is 
enantioselective against both maize (HD1-B and HD1-A) and human (HDAC1 and HDAC4) 
enzymes. In effect, the (R)-1b enantiomer is 3-fold more potent than (S)- 1b as maize HD1-B 
inhibitor.  n the case of 1c against maize HD1-A enzyme there is not a large difference of action 
between the enantiomers. As concerns the 2-aminoanilide 2c, the (R)-enantiomer showes an 
appreciable improvement in activity respect to the racemic form only against HDAC1 (table 10). The 
inhibitory data for the arylmethylaminocinnamylhydroxamates (3) and -2-aminoanilides (4) against 
hrHDAC1 and hrHDAC4 are reported in Table 8. In the case of the hydroxamates 3, the 
phenylmethylamino prototype 3a displayed 55.6% of HDAC1 inhibition at 5 µM, and the 
replacement of the phenyl ring with the 2- or 3-thienyl (compounds 3e or 3f) as well as2-naphthyl 
or 2-benzofuryl moiety (compounds 3j or 3k) highly improves this inhibitory action.  
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In the corresponding 2-aminoanilide 
series (compounds 4), the phenyl → 
thienyl replacement led to less potent 
compounds (see 4e and 4f vs 4a).  
However, in this 2-aminoanilide series 
this activity is promptly restored by 
replacing the thienyl ring (R1 
position) with the 2-pyridyl 
(compound 4g) and 3-quinolinyl 
(compoun
d 4o), and 
to a lesser 
extent 
with other 
related 
mono- or 
bicyclic 
rings (see 
for 
example 
4h, 4n, 
and 4k). 
Against 
HDAC, the majority of the tested 3 and 4 compounds displayed low or no inhibiting  activity. 
 Table 9. IC50 values of selected 1-4 derivatives 
against HDAC1, HDAC4, and HDAC6[a] 
cpd                               IC50 ± SD (µM) HDAC1 HDAC4 HDAC6 
1k 0.07 ± 0.01 4.55 ± 0.27 2.9 ± 0.12 
2c 2.0 ± 0.1 54.4 ± 3.6 5.3 ± 0.21 
3f 0.08 ± 0.004 78.3 ± 4.7 0.27 ± 0.02 
3g 0.31 ± 0.01 48.8 ± 2.44 0.15 ± 0.01 
4n 0.59 ± 0.02 86.6 ± 4.33 8.17 ± 0.49 
4o 1.38 ± 0.05 71.8 ± 3.6 102.7 ± 5.13 
[a] Data represent mean values of at least three separate experiments. 
Table 10. Anti-HDAC Activity of 1b, 1c, and 2c Pure Enantiomers[a] 
cpd 
IC50 ± SD (µM) % of inhibition at 5 µM 
HD1-B HD1-A hr HDAC1 
hr 
HDAC4 
1b 0.072 ± 0.003 0.080 ± 0.003 54.6 45.0 
l(S)-1b 0.170 ± 0.007 0.125 ± 0.006 45.2 33.3 
(R)-1b 0.056 ± 0.002 0.073 ± 0.004 59.0 51.1 
1c 0.089 ± 0.004 0.064 ± 0.002 44.5 42.4 
(S)-1c 0.101 ± 0.003 0.063 ± 0.003 29.5 39.2 
(R)-1c 0.040 ± 0.002 0.070 ± 0.003 49.8 49.2 
2c   56.2 47.6 
(S)-2c   52.6 26.7 
(R)-2c   78.9 48.3 
[a] Data represent mean values of at least three separate experiments. 
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 For selected 1-4 derivatives, IC50 values against HDAC1, HDAC4, and HDAC6 were determined 
(Table 9). Among them, 1k is 65- and 41-fold more potentto inhibit HDAC1 than HDAC4 and 
HDAC6, respectively, whereas 3f and 3g, as well as the HDAC4. Finally, the anilides 4o and, to a 
lesser extent, 4n show privileged HDAC1 inhibition. 
5.2.3. Molecular Modeling and Docking Studies. 
All the representing compounds of the titled derivatives 1-4 are able to inhibit HDAC1 with an  
Figure 23. Ligands/HDAC1 interactions around the catalytic Zinc ion. In turquoise are displayed all 
the residues within 3.5 Å from either the hydroxamate or the benzamide groups. In the left 
side are reported the hydroxamates (1k in gray, 3f in purple and 3g in cyan) and in the right 
window are depicted the 2-aminoanilides ((S)-2c in magenta, (R)-2c in purple, 4n in cyan and 
4o in gray). The surface pocket for the 2-aminoanilide moiety is highlighted in atom type 
coloring. Residue enumeration was taken by the Q13547 accession from UniProtKB protein 
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activity from 30 to 1000 times stronger than against HDAC4. In order to get some insights on the 
HDAC1 selectivity, the 1k, 2c, 3f, 3g, 4n, and 4o binding modes were analyzed in both human 
HDAC1 (modeled from HDAC2 co-crystallized with N-(4- aminobiphenyl-3-yl)benzamide 142, pdb 
entry code 3max) and human HDAC4 143, (pdb entry codes: 2vqj and 2vqm) by the means o 
Autodock 4.2. Into the modelled HDAC1 both the hydroxamate (1k, 3f and 3g) and 2- aminoanilide 
 (2c [both enantiomers], 4n and 4o) representative derivatives showed interactions and binding 
conformations similar to those of the reference experimental bound compounds (TSA, taken from the 
HDAC8 co-complex, pdb code 1t64, and N-(4-aminobiphenyl- 3-yl)benzamide from the HDAC2 co-
complex, pdb code 3max; Figure 23). Among the ligand/enzyme interactions, for hydroxamates (1k, 
Figure 24. Ligands/HDAC1 interactions along the enzyme channel. In turquoise are displayed the residues 
within 3.5 Å from anilide/aniline (CU+connected Ph) groups. In the left side are reported the hydroxamates 
(1k in gray, 3f in purple and 3g in cyan) and in the right window are depicted the 2-aminoanilides ((S)-2c in 
magenta, (R)-2c in purple, 4n in cyan and 4o in gray). The surface for π-π stacking is highlighted in atom 
type coloring. Residue enumeration was taken by the Q13547 accession from UniProtKB protein sequence 
database, (http://www.uniprot.org) The gray sphere represents the catalytic zinc ion 
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3f and 3g) the zinc ion chelation is the inhibition driving force, while for theweaker zinc chelating 2- 
aminoanilides (2c, 
4n and 4o) further 
interactions are 
visible in a pocket 
formed by His140, 
Gly149, Cys151 
and Gly300 (Figure 
24), at the 
beginning of the 14 
Å acetate escape 
tunnel 144. 
Nevertheless, 
others moieties 
play some roles in 
the inhibition 
potency, and in 
particular all the anilide/aniline (CU+connected phenyl group) moieties establish π-π interactions 
with the HDAC1’s Phe150 and_he205, while electrostatic interactions are placed between HDAC1-
Asp99 and the anilide/aniline nitrogen atom (Figure. 24). Regarding the CAP groups, although no 
interaction seems to be relevant for the inhibition potency, at a deeper interaction modes: a TSA-like 
mode, shared by 3f and 4n, where the dimethylaminophenyl (TSA), inspection the most active 
derivatives (1k, 3f, 3g and 4n) show that there are two preferred CAP the 3-thienyl (3f) and the 2- 
quinolinyl (4n) groups fit into a large cleft paved mainly by main and side chains of His28, Pro29, 
Figure 25. Ligands/HDAC1 interactions around the rim of the HDAC1 substrate 
entrance. In turquoise are displayed all the residues within 3.5 Å from the inhibitor 
CAP groups. In the figure are reported both the hydroxamates (1k in dark gray, 3f in 
pink and 3g in green) and the 2-aminoanilides (R)-2c in purple, 4n in cyan and 4o in 
light gray). The surface of HDAC1 is in atom type coloring. Residue enumeration 
was taken by the Q13547 accession from UniProtKB protein sequence database, 
(http://www.uniprot.org). 
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Asp99 and Phe150 residues, and a  narrow canyon delimited by Asn95, Asp99, Ser148, Gly149 and 
Phe205 where the 1k naphthylethylmethyl and the 3g 
pyridylmethyl groups fulfill the available space. On the 
other hand less active compounds,  such as 2c and 4o, 
although structurally related, where docked by Autodock 
with a different mode, in which the phenylethylmethyl (2c) 
and the 3- quinolinyl (4o) moieties are lying on a wide 
opened area described by His175, Tyr204 and Leu271 
(Figure 26). Differently from HDAC1, HDAC4 shows a 
wider substrate binding channel partially deprived of the 
acetate escape tunnel 145, at the side of the zinc ion. This 
lack prevents the 2-aminoanilide derivatives to reach 
effective chelating  distances thus lowering the activity against HDAC4 (Figure 25). The open wide 
Figure 27. Binding mode of 
derivative 1k (green) into HDAC4 
Figure 26.. HDAC4 Autodock proposed binding modes for the representative hydroxamates (left: 1k in 
gray, 3f in purple and 3g in cyan) and 2-aminoanilides (right: (S)-2c in magenta, (R)-2c in purple, 4n in 
cyan and 4o in gray). The gray sphere represents the catalytic zinc ion. 
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shape of the HDAC4 catalytic tunnel also has some negative influence for the hydroxamate series. 
The missing π-π sandwich, observed for HDAC1, prevents the inhibitors to be anchored to the tunnel, 
and the hydroxamate functions to properly chelate the zinc ion. Similarly as reported for the cocrystal 
structure 2vqm, only the hydroxamate carbonyl groups showed the needed distances to make 
electrostatic type interactions with the zinc ion, whereas the hydroxyl groups are on the average 5 Å 
away from the metal ion. Interestingly, among the tested derivatives in Table 9, 1k displayed the 
highest activity. A deeper inspection of 1k Autodock binding mode revealed that the central amide 
makes two strong hydrogen bonds with Phe227 and Pro298 (Figure 27), that in some way 
compensates the lack of a full zinc ion chelation. 
5.2.4. Effects on Acetylation Level of Histone (Histone H3) 
and Non-Histone (α-Tubulin) Substrates. p21 Induction. 
In order to determine the effects on the acetylation levels of histone H3 and α–tubulin for compounds 
1-4, all of them were tested at 5 µM for 24 h on human leukemia U937 cells and western blot 
analyses were performed with specific antibodies using SAHA and MS-275 as reference drugs. In the 
above conditions, the acylamino hydroxamates 1 as well as most of the related 2-aminoanilides 2 (see 
compounds 2a-g,k,l) were able to increase the acetylation levels of histone H3, having fair 
correlation with their HDAC1 inhibition activities (Figure 28 A).  Only few hydroxamates from the 1 
series (1a, 1g, and 1h) and none 2-aminoanilide from the 2 series were able to induce high acetylation 
of α-tubulin (Figure 28 B), suggesting a general low or no inhibitory activity of the above derivatives 
against HDAC6. Differently, among the arylmethylamino cinnamyl compounds 3 and 4, in general 
all of them gave an increase of both the acetyl-histone H3 and acetyl-α-tubulin levels, with no 
difference of the substrate used (Figures 29 C and 29 D). In particular, 3f-i, 3m-o, and 4k were been 
able to give an increase of α-tubulin acetylation higher than SAHA. p21 is a cell cycle inhibitor. 
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Typically the increase of expression of p21 is an effect reported  mainly for I HDAC inhibitors 146, 147. 
So in order to get some insights on the HDAC1 selectivity, western blot  was performed. 
Figure 28 B shows that, in general, both the hydroxamates 1 and the 2- aminoanilides 2 gave a high 
induction of p21, compounds 2 being in many cases (2b-i) more efficient than MS-275 and SAHA in 
the tested conditions. Conversely, the arylmethylaminocinnamyl hydroxamates 3 showed weak p21 
induction, lower than SAHA and MS-275, with the exception of 3a and 3e, that gave a high signal. 
The arylmethylaminocinnamyl anilides 4 were, in general, unable to induce p21 in these conditions, 
with the remarkable exception of 4h, 4m, and 4n, that showed a p21 induction level higher than (4h 
and 4n) or similar as (4m) those obtained with MS-275 and SAHA (Figure 29 D). 
Figure 28. Effects of compounds 1-2 (5 µM, 24 h) on 
acetylation levels of histone H3 and α–tubulin, and on p21 
induction, in U937 leukemia cells. Western blot analyses 
were performed with specific antibodies. (A), acetyl-H3 
assay on compounds 1 and 2; histone H1 was used for 
equal loading. (B), acetyl-α- tubulin and p21 assays on 
compounds 1 and 2; ERKs were used for equal loading. 
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5.2.5. Cell Cycle Analysis, Apoptosis Induction, Granulocytic 
All the compounds 1-4 were tested in the human U937 leukemia cell line in order to determine their 
Figure 29 Effects of compounds 3-4 (5 µM, 24 h) 
on acetylation levels of histone H3 and α–tubulin, 
and on p21 induction, in U937 leukemia cells. 
Western blot analyses were performed with 
specific antibodies. (C), acetyl-H3 assay on 
compounds 3 and 4; histone H4 were used for 
equal loading. (D), acetyl-α-tubulin and p21 
assays on compounds 3 and 4; ERKs were used 
for equal loading. 
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effects on cell cycle, apoptosis induction, 
granulocytic differentiation, and 
antiproliferative activity. SAHA, MS-
275, and/or HDAC42 were used as 
reference drugs. All the compounds were 
tested at 5 µM for 30 h.  
In general all the compounds showed an 
arrest of the cell cycle of U937 cells 
either at G2/M or G1/S phase, according 
to a general behaviour shown by the 
treatment of cancer cells with HDACi 
(Figure 30) 148, 149. In particular, some of 
the tested hydroxamates gave a block at 
the G2/M phase (including SAHA and 
HDAC42), others showed a cell cycle 
arrest at the G1/S phase. Differently, the 
2-aminoanilide derivatives 2 and 4, as 
well as MS-275, when altered the cell 
cycle, they always provided a block at the 
G1/S phase 
The induction of apoptosis was evaluated 
by caspase 3-7 activation (Figure 31). 
After treatment of U937 cells with 1-4 at 
5 µM for 30 h, some hydroxamates  Figure 30. Cell cycle analysis on U937 leukemia 
cells treated with compounds 1-4 at 5 µM for 30 h.
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belonging to the 1 series (1h-l) furnished the highest percent of apoptosis, higher than those obtained 
with SAHA and HDAC42 in this assay. In particular, 1k and 1l carrying as a CAP+CU group the 2-
(1- and 2- naphthyl)butyrylamino moieties, induced high, dose-dependent apoptosis more efficiently 
than SAHA, used as reference drug (Figure 34). 
The percent of apoptosis obtained with the other compounds active in this test was higher than (see, 
for example, 2l and 4d) or similar as that observed with SAHA (1a, 1c, 3a, 3j, 3l, 3m, 4e, 4f, and 4l). 
The benzamide MS-275 showed a modest apoptosis induction (7.7%) in this setting. The 
hydroxamates 1k and 1l as well as the 2-aminoanilides 2c and 4n were tested at 5 µM in U937 cells 
to evaluate their effects on cell proliferation (Figure 33) using SAHA (5 µM) as reference drug. The 
Figure 31.  Apoptosis induction on U937 leukemia 
cells by compounds 1-4, tested at 5 µM for 30 h. 
Figure 32. . Cytodifferentiation activity (evaluated as % 
of CD11c positive/PI negative cells) given by 
compounds 1-4 (5 µM, 30 h) on U937 leukemia cells. 
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cells were counted with Trypan Blue dye 
every 24 h for 3 days. 1k and 1l and, to a 
lesser extent, 4n and 2c showed to give a 
dose dependent arrest of the cell 
proliferation stronger than SAHA.  
The increased expression of the surface 
antigen CD11c was used as a marker of 
granulocytic differentiation in U937 
leukemia cells. The cells were treated with 
compounds 1-4 at 5 µM for 30 h, and then 
the percent values of CD11c 
positive/propidium iodide (PI) negative cells 
were determined (Figure 32). In these 
conditions, the majority of the 2-
aminoanilide derivatives (series 28 and 4) 
showed interesting (around 50% of 
CD11c+/PI- cells) cytodifferentiation 
properties, similarly as that observed with 
MS- 275. In particular, 2b, 2c, 2e, and 2i 
(bearing as a CAP+CU a methyl-, ethyl-, 
and iso-propyl substitution at the 
phenylacetylamino moiety, or a 1-
naphthylacetylamino group, respectively), 
as well as 4g, 4h, 4n, and 4o (showing the 
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2- and 3-pyridyl or the 2- or 3-quinolinyl ring as a CAP, respectively), furnished values of 
CD11c+/PI- cells similar as or higher than that of MS-275. Dose-response curves were generated for 
the top scoring compounds 2c and 4n, obtaining dose-dependence differentiation activity from 1 to 5 
µM (Figure 34), while at 25 µM a lesser number of CD11c+/PI- cells was registered, probably due to 
cytotoxicity problems (Figure 36). 
Among the hydroxamates 1 and 3, the majority of those from the 3 series furnished a differentiating 
activity ranging from 30 to 40% of CD11c+/PI- cells, whereas those from the 1 series were less 
active. Due to their intense coloration, some compounds could not be tested in the CD11c assay. 
Thus, they were tested on U937 cells at 5 µM for 30 h by using the Nitro-tetrazolium Blue (NBT) 
assay, a general test for differentiation of cells. All the tested compounds (3c, 3j, 3n, 4c, 4i, 4j, and 
4l) were less efficient than MS-275 in this test to induce cell differentiation (Figure 37).  
5.3. Materials and methods 
Melting points were determined on a Buchi 530 melting point apparatus and are uncorrected. Infrared 
(IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One instrument. 1H NMR spectra 
were recorded at 400 MHz on a Bruker AC 400 spectrometer; chemical shifts are reported in δ (ppm) 
Figure 36. Cytotoxicity exerted by 2c and 4n in 
U937 cells 
Figure 37. NBT test performed on selected 3 and 4 
derivatives. 
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units relative to the internal reference tetramethylsilane (Me4Si). All compounds were routinely 
checked by TLC and 1H NMR. TLC was performed on aluminumbacked silica gel plates (Merck 
DC, Alufolien Kieselgel 60 F254) with 9 spots visualized by UV light. All solvents were reagent 
grade and, when necessary, were purified and dried by standard methods. Concentration of solutions 
after reactions and extractions involved the use of a rotary evaporator operating at reduced pressure 
of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulphate. Analytical results are 
within ±0.40% of the theoretical values. A SAHA sample for biological assays was prepared as 
previously reported 150. MS-275 and HDAC42 were synthesized according to the literature 151, 124. All 
chemicals were purchased from Aldrich Chimica, Milan (Italy), or from Lancaster Synthesis GmbH, 
Milan (Italy), and were of the highest purity. 
5.3.1. Experimental section 
5.31 Chemistry
5.3.1.1.1. General Procedure for the Synthesis of Ethyl 3-(4- Acylaminophenyl)-2-
propenoates (5a-n). Ethyl 3-[4-(2- Phenylbutyryl)aminophenyl]-2-propenoate (5c). 2-
Phenylbutyryl chloride (7.32 mmol, 1.33 g) and triethylamine (15.22 mmol, 2.12 mL) were added to 
a solution of ethyl 3-(4-aminophenyl)-2-propenoate hydrochloride[43] (6.1 mmol, 1.39 g) in dry 
dichloromethane (20 mL) at 0 °C. After stirring at room temperature for 4 h, the reaction mixture was 
poured into water (50 mL), the organic layer was separated, and the aqueous one was extracted with 
chloroform (2 × 50 mL). The combined organic solution was washed with water (100 mL) and brine 
(100 mL), and was dried and evaporated to dryness. The residual solid was purified by crystallization 
from cyclohexane to yield the pure 5c. 1H NMR (CDCl3) δ 0.93 (m, 3H, CH2CH3), δ 1.32 (m, 3H, 
OCH2CH3), δ 1.85-2.25 (m, 2H, CH2CH3), δ 3.40 (m, 3H, PhCHCO), δ 4.25 (OCH2CH3), δ 6.34 
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 (d, 1H, PhCH=CHCOOEt), δ 7.26-7.49 (m, 9H, benzene protons), δ 7.60 (d, 1H, PhCH=CHCOOEt). 
5.3.1.1.2. General Procedure for the Synthesis of 3-(4-Acylaminophenyl)-2- propenoic 
Acids (6a-n). 3-[4-(2-Phenyl-4- pentenoylamino)phenyl]-2-propenoic Acid (6f): A 
mixture of ethyl3-[4-(2-phenyl-4-pentenoylamino)phenyl]-2-propenoate 5f (0.57 mmol, 0.20 g), 
lithium hydroxide hydrate (1.14 mmol, 0.048 g), and tetrahydrofuran (15 mL) was stirred at room 
temperature. After 24 h, 2 N HCl was added to the mixture until the pH was 5, and the obtained solid 
was filtered and recrystallized to yield pure 6f. 1H NMR (DMSOd6) δ 2.48-2.76 (m, 2H, 
CH2CH=CH2), δ 3.50 (m, 1H, PhCHCO), δ 5.00 (m, 2H, CH2CH=CH2), δ 5.72 (m, 1H, 
CH2CH=CH2), δ 6.35 (d, 1H, PhCH=CHCOOEt), δ 7.31-7.60 (m, 10 H, benzene protons and 
PhCH=CHCOOEt), δ 10.30 (s, 1H, CONHPh). 
5.3.1.1.3. General Procedure for the Synthesis of the 3-(4- Acylaminophenyl)-N-
hydroxy-2-propenamides (1a-n) and the 3[4-(Arylalkylamino)phenyl]-N-hydroxy-2-
propenamides (3a-o). 3- [4-(2,3 Diphenylpropionyl)aminophenyl]-N-hydroxy-2- 
propenamide (1h): Ethyl chloroformate (1.26 mmol, 0.12 mL) and triethylamine (1.37 mmol, 0.19 
mL) were added to a cooled (0 °C) solution of 3-[4-(2,3-diphenylpropionyl)aminophenyl]-2-
propenoic acid 6h (1.05 mmol, 0.39 g) in dry THF (10 mL), and the mixture was stirred for 10 min. 
The solid was filtered off, and O-(2-methoxy-2- propyl)hydroxylamine (3.15 mmol, 0.23 mL) was 
added to the filtrate. The solution was stirred for 15 min at 0 °C, then was evaporated under reduced 
pressure, and the residue was diluted in methanol (10 mL). Amberlyst 15 ion-exchange resin (105 
mg) was added to the solution of the O-protected hydroxamate, and the mixture was stirred at room 
temperature for 1 h. Afterwards, the reaction was filtered and the filtrate was concentrated in vacuo to 
give the crude 1h, which was purified by crystallization. 1H NMR (DMSOd6) δ 3.05 (m, 1H, 
PhCH2), δ 3.60 (m, 1H, PhCH2), δ 3.75 (m, 1H, PhCHCO), δ 6.36 (d, 1H, PhCH=CHCOOEt), δ 
7.15-7.70 (m, 15H, benzene protons and PhCH=CHCOOEt), δ 9.00 (s, 1H, OH), δ 10.23(s, 1H, 
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CONHPh), δ 10.85 (s, 1H, NHOH). 
5.3.1.1.4. General Procedure for the Synthesis of the N-(2-Aminophenyl)-3- (4-
acylaminophenyl)-2-propenamides (2a-l) and the N-(2- Aminophenyl)-3-[4-
(arylalkylamino)phenyl]acrylamide (4a-o). N- (2-Aminophenyl)-3-[4-(quinolin-2- 
ylmethylamino)phenyl]acrylamide (4n): Triethylamine (1.96 mmol, 0.27 mL) and BOP 
reagent (0.59 mmol, 261 mg) were added under nitrogen atmosphere to a solution of compound 8n 
(0.49 mmol, 0.15 mg) in dry DMF (5 mL), and the resulting mixture was stirred for 30 min. After this 
time, 1,2-phenylendiamine (0.49 mmol, 0.053 mg) was added and the stirring was continued for 
further 30 min. The reaction was quenched by water (30 mL) and the precipitate was filtered, washed 
with water (3 × 30 mL) and dried. The solid residue was chromatographed on silica gel eluting with 
ethyl acetate/chloroform 1/1 to provide the desired compound 4n, that was recrystallized by 
acetonitrile/methanol. 1H NMR (DMSO-d6) δ 4.56-4.58 (d, 2H, ArCH2NH), 4.86 (s, 1H, PhNH2), 
6.52-6.56 (m, 2H, aniline protons), 6.63-6.65 (d, 2H, benzene protons), 6.68-6.70 (d, 1H, 
PhCH=CHCONHPh), 6.80 (t, 1H, aniline proton), 7.01 (t, 1H, aniline proton), 7.28-7.35 (m, 4H, 
benzene protons, PhCH=CHCONHPh and ArCH2NH), 7.54-7.73 (m, 2H, quinoline protons), 7.90 (t, 
1H, quinoline proton), 7.96 (d, 1H, quinoline proton), 8.29 (d, 1H, quinoline proton), 9.14 (s, 1H, 
PhNHCO). 
5.3.1.1.5. General Procedure for the Synthesis of Ethyl 3-[4- 
(Arylmethylamino)phenyl]-2-propenoates (7a-o). Ethyl 3-[4- (Benzofuran-2-
ylmethylamino)phenyl]-2-propenoate (7k): Ethyl-4-aminocinnamate (7.52 mmol, 1.44 g) and 
acetic acid (1 mL) were added to a solution of benzofuran-2-carboxaldehyde (6.84 mmol, 1.0 g) in 
methanol (10 mL), and the resulting mixture was stirred at room temperature for 1 h. Then the 
mixture was cooled at 0 °C, and sodium cyanoborohydride (13.68 mmol, 0.80 g) was added. After 30 
min, the solvent was removed and the residue was eluted with water (50 mL) and extracted with ethyl 
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acetate (3 × 30 mL). The organic layers were washed with sodium chloride solution (3 × 30 mL), 
dried with sodium sulphate and concentrated. The organic residue was chromatographed on silica gel 
eluting with ethyl acetate/n-hexane 1/5, to afford the pure product 7k as a yellow solid that was 
recrystallized by cyclohexane. 1H NMR (CDCl3) δ 1.28-1.32 (t, 3H, CH2CH3), δ 4.19- 4.24 (q, 2H, 
OCH2CH3), δ 4.47 (s,1H, ArCH2NH), δ 4.49 (m, 3H, ArCH2NH and ArCH2NH), δ 6.18-6.22 (d, 
1H, PhCH=CHCO), δ 6.59 (s, 1H, benzofuran protons), δ 6.64-6.66 (d, 2H, benzene protons), δ 7.18-
7.24 (m, 2H, benzofuran protons), δ 7.35-7.37 (d, 2H, benzene protons), δ 7.41-7.43 (d, 1H, 
benzofuran protons), δ 7.47-7.49 (d, 1H, benzofuran protons), δ 7.55-7.59 (d, 1H, PhCH=CHCO). 
5.3.1.1.6. General Procedure for the Synthesis of 3-[4- (Arylalkylamino)phenyl]-2-
propenonic Acids (8a-o). 3-[4-(3- Pyridylmethylamino)phenyl]-2-propenoic acid (8h):  
A mixture of 7h (1.42 mmol, 0.4 g), 2 N KOH (5.68 mmol, 0.32 g, 2.84 mL), and ethanol (15 mL) 
was stirred at room temperature overnight. Afterward, the solution was poured into water (50 mL) 
and extracted with ethyl acetate (3 × 20 mL). 2 N HCl was added to the aqueous layer to reach pH 5, 
and the obtained precipitate was filtered and dried to give the pure compound 8h, which was 
recrystallized by acetonitrile. 1H NMR (DMSO-d6) δ 4.33 (s, 1H, ArCH2NH), δ 6.09-6.13 (d, 1H, 
PhCH=CHCOOH), δ 6.56-6.58 (d, 2H, benzene protons), δ 6.85-6.88 (t, 1H, ArCH2NH), δ 7.29-7.40 
(m, 4H, benzene protons, PhCH=CHCOOH, pyridine proton), δ 7.68-7.70 (d, 1H, pyridine proton), δ 
8.40-8.42 (d, 1H, pyridine proton), δ 8.53-8.54 (s, 1H, pyridine proton), δ 11.9 (s, 1H, COOH). 
5.312 EnatiomerSps.
HPLC enantioseparations were performed by using stainless-steel Chiralpak IA (250 x 4.6 mm I.D. 
and 250 x 10 mm I.D.) (Daicel, Chemical Industries, Tokyo, Japan) columns. HPLC-grade solvents 
were supplied by Carlo Erba (Milan, Italy). HPLC apparatus consisted in a Perkin Elmer (Norwalk, 
CT, USA) 200 lc pump equipped with a Rheodyne (Cotati, CA, USA) injector, a HPLC Dionex (CA,  
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USA) Model TCC-100 oven and a Jasco (Jasco, Ishikawa-cho, Hachioji City, Tokyo, Japan) Model 
2095 Plus UV/CD detector. The sign of optical rotation was on-line monitored by using a Perkin-
Elmer polarimeter model 241 equipped with Hg/Na lamps and a 40 µl flow-cell. The mobile phases 
were filtered and degassed by sonication immediately before using. In analytical enantioseparations, 
standard solutions were prepared by dissolving 1-3 mg of sample, into 10 ml of mobile phase. The 
injection volume was 10-20 µl. In semipreparative enantioseparation a 1 mL sample loop was used. 
After 10 semipreparative separation, the collected fractions were analyzed by chiral analytical 
columns to determine their enantiomeric excess (ee). The column hold-up time (t0 = 3.0 min for the 
250 x 4.6 mm i.d. column) was determined from the elution of an unretained marker (toluene), using 
ethanol as eluent, delivered at a flow-rate of 1.0 mL/min. The mobile phase and the corresponding 
analytical chromatographic data for each resolved compound are summarized as follows: 1b: 
nhexane- ethyl acetate-ethanol-trifluoroacetic acid 80/20/10/0.1 (v/v/v/v), k1 = 1.48, α = 1.36, Rs = 
3.23; 1c: n-hexane-ethyl acetate-ethanoltrifluoroacetic acid 80/20/10/0.1 (v/v/v/v), k1 = 1.26, α = 
1.61, Rs = 4.05; 2c: n-hexane-ethanol 30/70 (v/v), k1 = 0.73, α = 1.66, Rs = 3.89. k1: retention factor 
of the first eluted enantiomer, defined as (t1 – t0)/t0 where t0 is the void time of the column; α: 
enantioselectivity factor defined as k2/k1; Rs: resolution factor defined as 2(t2-t1)/(w1+w2) where t1 
and t2 are retention times and w1 and w2 are band widths at the baseline in time units. Other 
analytical chromatographic conditions: flow-rate, 1.0 mL/min; temperature, 25 °C; detector: UV at 
300 nm. Specific rotations were measured at 589 nm by a Perkin-Elmer polarimeter model 241 
equipped with a Na lamp. The volume of the cell was 1 ml and the optical path was 10 cm. The 
system was at a temperature of 20°C by a Neslab RTE 740 cryostat. The circular dichroism (CD) 
spectra of the enantiomers of 1b and 1c, dissolved in ethanol, in a quartz cell (0.1 cm-path length) at 
25°C, were measured by using a Jasco Model J-700 spectropolarimeter. The spectra are average 
computed over three instrumental scans and the intensities are presented in terms of ellipticity values 
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 (mdeg). 
5.31 HomlgyMdes,cuar inDkSts. 
All molecular modeling software run on Beowulf cluster running the operating system is GNU/Linux 
Debian 5.0-Lenny using MPI (Message Passing Interface) libraries for parallel processes. HDAC1 
model preparation. HDAC1 structure was prepared using the deposited sequence in the Universal 
Protein Resource 152. (UniProt) (entry code Q13547) The homology model was automatically 
obtained by feeding the The Protein Model Portal (PMP) Server 153 with the above sequences. The 
PMP returned a HDAC1 model made using the HDAC2/N-(4-aminobiphenyl-3-yl)benzamide 
complex 138 chain B as template (pdb entry code 3max, 94% sequence identity). The model was then 
refined by AMBER 8.0 program using the following protocol. First, the experimental bound 
conformation of N-(4- aminobiphenyl-3-yl)benzamide as found in the template was merged into the 
HDAC1 structure. AM1-BCC charges was calculated on the ligand employing the antechamber 
module of Amber 8.0 using the xLeap Amber module, the starting complex was added of the 
hydrogen atoms and solvated in a octahedral box of TIP3P water with each box side at least 10.0 Å 
away from the nearest atoms of the complex. Sodium ions were included to neutralize the charge of 
the system. The ions were placed randomly in the system 10 Å away from the nearest atoms. The 
hydrogen atoms, counter ions and water molecules were then minimized for 1000 iterations. Finally 
the whole complex was relaxed for 5000 iterations. HDAC4 preparation. HDAC4 structures144 were 
retrieved from RCSB PDB (pdb entry codes: 2vqj and 2vqm) co-crystallized with a 
trifluoromethylketone and a hydroxamic acid inhibitors. The structures were refined by AMBER 8 
program using the previous described protocol as used for HDAC1.  
Docking procedure. The docking studies were performed using Autodock 4.2 . The proteins, prepared 
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as described above, (HDAC1 and HDAC4) were aligned by means of UCSF Chimera 154 
MatchMaker tool. The structure of the inhibitors to be docked were builty by the Chemaxon sketch 
module 155. AutoDock Tools package 1.5.4 (http://mgltools.scripps.edu/) was employed to generate 
the docking input files and and to analyze the docking results; the same procedure as described in the 
manual was followed. A grid box size of 51 x 58 x 57 points spacing of 0.375 Å were used, centered 
to the bound co-crystallized inhibitors and covered most of the catalytic channels of the enzymes. 
Two hundred structures, i.e. 200 runs, were generated using Lamarckian genetic algorithm. A default 
protocol was applied, with an initial population of 150 randomly placed individuals, a maximum 
number of 2.5 x 106 energy evaluations, and a maximum number of 2.7 x 104 generations. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used. The docking results were clustered using 
a 2.0 Å tolerance. In all the cases lowest energy docked conformation belonged to the most populated 
cluster. In the case of HDAC4 100 runs for each structure were generated (cross- Docking 156) and the 
results of either dockings were clustered using the Autodock internal clustering algorithm. 
5.314 Biolgcasy
5.3.1.4.1. In Vitro Maize HD1-B and HD1-A Enzyme Inhibition. Radioactively labeled 
chicken core histones were used as the enzyme substrate according to established procedures. 
Purification of maize HD1-A and HD1-B enzymes were performed in part as recently described 157-
160
. Briefly, frozen seedlings of maize were ground to powder in a mortar. Chromatin was prepared as 
described 161 which results in a soluble cytoplasmic fraction that contains HD1-A and a “chromatin 
fraction” that contains HD1-B. Cytoplasmic and nuclear fractions were further separated by ion 
exchange chromatography (Q-Sepharose) with subsequent size exclusion chromatography (S200). 
Resulting protein fractions with HDAC activity were used for inhibition assays. The enzymatic 
activity liberated tritiated acetic acid from the substrate, which was quantified by scintillation 
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counting. IC50 values are results of triple determinations. A 50 µL sample of partially purified 
endogenous (native) maize enzymes was incubated (30 min, 30 °C) with 10 µL of total [3H]acetate-
prelabeled chicken reticulocyte histones (2 mg/mL). Reaction was stopped by addition of 36 µL of 1 
M HCl/0.4 M acetate and 800 µL of ethyl acetate. After centrifugation (10 000 g, 5 min), an aliquot 
of 600 µL of the upper phase was counted for radioactivity in 3 mL of liquid scintillation cocktail. 
The compounds were tested at a starting concentration of 40 µM, and active substances were diluted 
further. SAHA and HDAC42 were used as the reference compounds, and blank solvents were used as 
negative controls. 
5.3.1.4.2. Fluorimetric Human Recombinant HDAC1 and HDAC4 Assays. The HDAC 
Fluorescent Activity Assay for HDAC1 and HDAC4 is based on the Fluor de Lys Substrate and 
Developer combination (BioMol), and has been carried out according to supplier’s instruction and as 
previously reported. First, the inhibitors and purified recombinant HDAC1 or HDAC4 enzymes have 
been pre-incubated at room temperature for 15 minutes before substrate addition, the Fluor de Lys 
Substrate, which comprises an acetylated lysine side chain. For HDAC4 assay, the HDAC4-selective, 
non-histone substrate reported by Lahm et al 142 has been used. Full length HDAC1 and HDAC4 with 
C-terminal His tag were expressed using baculovirus systems. Deacetylation sensitizes the substrates 
that, in the second step, treated with the developer produce a fluorophore. Fluorescence has been 
quantified with a TECAN Infinite M200 station. IC50 data were analyzed using GraphPad Prism 
Software. 
5.3.1.4.3. Cellular Assays. Cell Lines and Cultures. U937 cell line was cultured in RPMI with 
10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin-B, 
10 mM HEPES and 2 mM glutamine. U937 cells were kept at the constant concentration of 200000 
cells per millilitre of culture medium.  
Ligands and Materials. SAHA, MS-275, HDAC42, and the cinnamylbased compounds 1-4 were 
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dissolved in DMSO and used at 5 µM as described 162. 
5.3.1.4.4. Histone H3 and α-Tubulin Acetylation in U937 Cells. For quantification of 
histone H3 acetylation, 5 µg of total histone extracts were separated on a 15% polyacrylamide gel and 
blotted as described 162. Western blots were shown for acetylated histone H3 (Upstate), and histone 
H1 (Abcam) was used to normalise for equal loading. For determination of α-tubulin acetylation, 25 
µg of total protein extracts were separated on a 10% polyacrylamide gel and blotted as described 161. 
Western blots were shown for acetylated α-tubulin (Sigma) and total ERKs (Santa Cruz) were used to 
normalise for equal loading. 
5.3.1.4.5. Determination of p21WAF1/CIP1 Induction in U937 Cells. 100 µg of total 
protein extracts were separated on a 15% polyacrylamide gel and blotted as previously described 163, 
164
. Western blots were shown for p21 (Transduction Laboratories) and total ERKs (Santa Cruz) were 
used to normalise for equal loading. 
5.3.1.4.6. Cell Cycle Analysis on U937 Cells. 2.5 x 105 cells were collected and resuspended in 
500 µL of an hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 50 µg/mL propidium iodide 
(PI), RNAse A). Cells were incubated in the dark for 30 min. Samples were acquired on a FACS-
Calibur flow cytometer using the Cell Quest software (Becton Dickinson) and analysed with standard 
procedures using the Cell Quest software (Becton Dickinson) and the ModFit LT version 3 Software 
(Verity) as previously reported 163. All the experiments were performed 3 times.  
5.3.1.4.7. FACS Analysis of Apoptosis on U937 Cells. Apoptosis was measured with the 
caspase 3-7 detection (B-Bridge) method; samples were analysed by FACS with Cell Quest  
technology (Becton Dickinson) as previously reported 164. 
5.3.1.4.8. Proliferation Assay on U937 Cells. U937 cells have been cultured in 24 multiwells 
(Corning) at the initial dilution of 200 000 cells/mL with vehicle or with HDAC inhibitors used at the 
indicated concentrations. Every 24 h, living U937 cells have been counted using the Trypan Blue dye 
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(Sigma) for dead cells staining. The graph shows data plotted after three days. The experiment has 
been carried out in triplicate. In parallel, an MTT colorimetric proliferation assay (Promega) has been 
carried out in duplicate (data not shown) following manufacturer’s instructions. 
5.3.1.4.9. Granulocytic Differentiation on U937 Cells. Granulocytic differentiation was 
carried out as previously described 164. Briefly, U937 cells were harvested and resuspended in 10 µL 
phycoerythrineconjugated CD11c (CD11c-PE). Control samples were incubated with 10 µL PE 
conjugated mouse IgG1, incubated for 30 min at 4 °C in the dark, washed in PBS and resuspended in 
500 µL PBS containing PI (0.25 µg/mL). Samples were analysed by FACS with Cell Quest 
technology (Becton Dickinson). PI positive cells have been excluded from the analysis. 
5.3.1.4.10. Granulocytic Differentiation on U937 Cells: Nitroblue Tetrazolium (NBT) 
assay. 2×106 U937 cells were harvested and washed in 500 microL of PBS/BSA(1mg/mL). 500 µL 
of 0.2% NBT (Sigma) in PBS/BSA 0.1% were added. 200 ng/mL of 12-O-tetradecanoylphorbol-13-
acetate (TPA, Sigma) were added. After a gentle stirring, samples (3c, 3j, 3n, 4c, 4i, 4j, 4l, and MS-
275 as reference drug, all at 5 µM) were incubated at 37 °C for 30 min. The formazan deposits were 
dissolved with 500 µL of lysis buffer (50% N,N-dimethylformamide, 20% SDS, pH 4.7). The optical 
density (OD) was measured at 570 nm. 
6. Study of 1,4-Dihydropyridine Structural Scaffold: 
Discovery of Novel Sirtuin Activators and Inhibitors 
In regard to their roles in physiology and pathology, sirtuins are multifaceted enzymes that regulate a 
variety of cellular functions, from controlling gene expression and genome maintenance to longevity 
and metabolism 165-168. Several diseases are reported being correlated to SIRT activity disfunctions. In 
order to find some Sirtuin modulating compounds this work, starting from the information that 
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nicotinamide is a micromolar SIRT inhibitor 169 and that iso-nicotinamide is a SIRT activator 170 , 
shows the exploration of the known scaffold 1,4-dihidropiridinic ring, obtained for the simpler 
pirydinic ring. Using a three-component (aliphatic/aromatic amine, ethyl propiolate, and 
benzaldehyde), one-pot reaction, I prepared some 3,5- dicarbethoxy-, 3,5-dicarboxy-, and 3,5-
dicarboxamido-4- phenyl-1,4-dihydropyridines 1a-d, 2a-d, and 3a-d, respectively. All of them were 
tested against human SIRT1, SIRT2, and SIRT3. 
6.1. Chemistry 
The 3,5-dicarbethoxy-4-phenyl-1,4-dihydropyridines 1a-d were prepared by cyclocondensation 
between benzaldehyde, ethyl propiolate 
and the opportune amine, heated at 80 
ͦC in glacial acetic acid. Furthermore, 
compounds 1a-d underwent alkaline 
hydrolysis at 80 ͦC in ethanol to furnish 
the corresponding 3,5-dicarboxy 
derivatives 2a-d. Finally, these last 
compounds reacted with triethylamine, 
benzotriazole-1- 
yloxytris(dimethylamino)phosphonium 
hexafluorophosphate (Bop reagent), 
and 33% aqueous ammonia under N2 atmosphere to give the 3,5-diamides 3a-d (Scheme 2).Among 
the synthesized derivatives, compounds 1b, 1c, and their corresponding acids 2b and 2c are known in 
the literature (1b and 2b 171, 1c,172 2c173). Chemical and physical data for compounds 1-3 are reported 
in Table 11.  
Scheme 2.a: CH3COOH, 80°C; b: 5N KOH, EtOH, 80°C; c: 
1) Et3N, Bop Reagent, dry DMF, r.t., 30 min., N2 
atmosphere, 2) 33% aqueous NH3, dry DMF, r.t., 30 min., N2 
atmosphere. 
CHO
NH2
O
EtO OEt
O
N
R
X
O
X
O
R=
a
b
R
X= OEt MC 2733, MC 2734,
MC 2562, MC 2735
X= OH MC 2736, MC2737,
MC 2738, MC 2563c
X= NH2 MC 2743, MC 2744,
MC 2745, MC 2566
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Table. 11. Chemical and physical data for compounds 1-3 
Compounds R X M. P. (°C) 
Recrystallization 
solvent 
Yield 
(%) 
MC 2733 
 
OEt 100-102 cyclohexane 75 
MC 2736 
 
OH 220-222 methanol 87 
MC 2743 
 
NH2 >250 methanol 72 
MC 2734 
 
OEt 143-145 Cyclohexane/benzene 60 
MC2737 
 
OH 240-242 methanol 83 
MC 2744 
 
NH2 
194-
196 Acetonitrile/methanol 69 
MC 2562 
 
OEt 139-141 Cyclohexane/benzene 78 
MC 2563 
 
OH 191-193 Acetonitrile/methanol 86 
MC 2566 
 
NH2 >250 methanol 74 
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MC 2735 
 
OEt 91-93 cyclohexane 68 
MC 2738 
 
OH 218-220 Acetonitrile/methanol 85 
MC 2745 
 
NH2 >250 methanol 70 
6.2. Results and Discussion 
6.2.1. SIRT1, -2, and -3 Modulator Activity: Enzyme and 
Functional Assays 
All the prepared compounds were tested against human SIRT1, SIRT2, and SIRT3 at 50 µM, using 
the Fluor de Lys fluorescent biochemical assay (BioMol) (Figure 38). The results showed that the 
new 1,4-dihydropyridine (DHP) derivatives have different activities for different substituent at the N1 
and/or at the 3,5 position of  the DHPring. In particular, a cyclopropyl, a phenyl, or a phenylethyl 
group at N1 make the compound SIRT1-2 inhibitor.  
The highest SIRT1 inhibition activities were seen with the N1- phenyl analogues bearing a carboxy 
or a carboxamido group at the 3,5 positions (2b and 3b, 86.6% and 89.1% of SIRT1 inhibition at 50 
µM), followed by the 1-phenethyl- and 1- phenyl-3,5-dicarbethoxy derivatives 1d and 1b (76.6% and   
63.6%of inhibition, respectively). 
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Against SIRT2, the diester compounds 1a, 1b, and 1d showed the highest inhibition activity, with      
 comparable potency (1a: 53.7%; 1b: 51.3%; 1d: 49.6% of SIRT2 inhibiting activity at 50 µM). 
Surprisingly, the DHPs bearing a benzyl group at the N1 position, regardless of their substitution at 
the 3,5 positions (either a carbethoxy (1c), carboxy (2c), or carboxamido (3c) moiety), did not inhibit 
the tested sirtuins but behaved as potent, dose-dependent SIRT1, -2, and -3 activators (Figure 40). 
The most potent compounds are 1c and 2c that showed the strongest SIRT1 activation with a EC150 
(effective concentration able to increase the enzyme activity of 150%) around 1 µM, while the 3,5-
dicarboxamide 3c was less effective (EC150=36 µM). In SIRT2 assay the dicarboxy derivative 2c 
displayed the highest activating 
potency (EC150=15 µM), 
followed by the dicarbethoxy 
compound 1c (EC150=25 µM), 
while 3c was less efficient. 
Against SIRT3 assay, although 
being less effective than in 
SIRT1 and -2 assays, 1c and 2c 
exhibited higher activation 
activity than 3c (EC150 values: 
1c and 2c, around 50 µM; 3c, 
>50 µM). α-tubulin is a known 
substrate for SIRT2.  
In order to determine their 
effect on acetylation level of 
this substrate, the new SIRT Figure 39.  Effects of SIRT activators MC2562, MC2563, and MC2566 (50 µM) on α-tubulin acetylation in SAHA-pretreated U937 cells 
Figure 38. SIRT1, -2, and -3 modulating activities of compounds 
1-3 tested at 50 µM. 
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activators 1c, 2c, and 3c were 
tested in functional assay. Western 
blot analysis was performed on the 
human leukemia U937 cell line. 
Because U937cells typically show 
weak basal acetylation levels for α-
tubulin 174, 175, the expected 
hypoacetylation effect from the 
SIRT activators may be difficult to 
appreciate.  
Thus in order to amplify the 
acetylation of α-tubulin 174, 175, the 
cells were pretreated with the well-
known HDAC inhibitor SAHA176 
(suberoylanilide hydroxamic acid, 
3 h, 5 µM). After the wash out at 3 
h of SAHA incubation, the effects 
of 1c, 2c, and 3c, used at 50 µM, in 
comparison with vehicle or SAHA 
treatment (5 µM) on tubulin 
acetylation levels after 5 h of 
treatment, have been assessed.  
As depicted in Figure 39, the tested 
N-benzyl-DHP compounds induced 
Figure 40. Dose-dependent SIRT1, -2, and -3 activation by the N-
benzyl DHPs 1c, 2c, and 3c. 
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hypoacetylation on α-tubulin in U937 cells. In SAHA-untreated U937 cells, the SIRT activators 
showed no effects on tubulin acetylation. 
6.2.2. Cell Cycle Analysis, Apoptosis Induction, Granulocytic 
differentiation in U937 cell line 
All the synthesized modulators were tested, initially, in the human U937 leukemia and in MCF-7 
breast cancer cell lines, to study their effects on cell cycle, apoptosis induction, and granulocytic 
differentiation 177. When tested in the MCF-7 breast cancer cell lines, these compounds did not show 
significant effects. A treatment at 50 µM for 30 h on U937 cell line, displayed only marginal effects. 
(Figure 41). In particular, the three SIRT activators 1c, 2c, and 3c were able to  
• arrest the cell cycle at the G1/S phase, with an effect that could be related to p53 
deacetylation as well as to effects on multiple targets within the cell,  
• induce a slight apoptotis (3-4%), in particular the diester inhibitors 1a, 1b, and 1d  
• don’ t give any granulocytic differentiation, except the diethyl 1-phenethyl-4-phenyl-1,4 
dihydropyridine-3,5-dicarboxylate 1d, that show a significant (12.3%) increase, with an 
effect that seems not to be related to its SIRT1 and -2 inhibition activity.  
6.2.3. Involvement in mithocondrial biogenesis  
The most studied natural compound for SIRT1 activator is resveratrol although the activation effects 
of resveratrol on SIRT activity are controversial 178. Activation of SIRT1 by resveratrol has been 
claimed to partially mimic caloric restriction and resveratrol delays aging parameters in mice 179. In 
spite of the appeal of SIRT1 activation for improving metabolic parameters in mammals, an increased 
cancer risk is a concern if activation of SIRT1 leads  to unhealthy repression of p53 activity. It would 
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be highly desirable to find an optimal condition or drug that would activate SIRT1 and not increase 
human cancer risk. Besides inducing cell growth arrest and apoptosis, p53   activation also   
 induces cellular senescence in response to  
oxidative stress. The promyelocytic leukemia 
protein (PML) nuclear bodies are discrete 
nuclear substructures and represent the natural 
accumulation sites of PML proteins 180. The 
size and number of PML nuclear bodies are 
altered during the cell cycle and in response to 
various cellular and environmental stresses 181. 
There are seven splice variants of PML named 
PML I–VII in mammalian cells. PML IV 
interacts with HDACs in the regulation of p53 
function and induction of premature 
senescence 180, 182-184. Upon PML IV 
upregulation or oncogenic Ras expression, 
SIRT1 is recruited to nuclear bodies and 
interacts directly with PML IV and p53 to 
repress p53-dependent transactivation by 
deacetylation of p53180. The recruitment of 
SIRT1 also rescues PML-induced cellular 
senescence by inhibiting p53 acetylation180. 
This phenomenon of senescence inhibition by 
SIRT1 also exists in human endothelial 
Figure 41. Effects of 1-3 (50 µM, 30 h) on cell cycle, 
apoptosis induction, and granulocytic differentiation in 
human U937 leukemia cells. 
 PhD course in Pasteurian Sciences, XXIV cicle, Rome, 29th February, 2012 
 
70 6. Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and 
Inhibitors 
cells185. 
Endothelial 
cells with 
down-
regulated 
SIRT1 
exhibit 
increased 
acetylation of 
p53 and 
premature 
senescence-
like 
phenotype. 
Conversely, 
overexpressi
on of SIRT1 
prevents cells 
from  
physiological 
alteration 
toward senescence185. Therefore, SIRT1 seems to exert a protective role against p53-dependent 
senescence under multiple cellular stresses although it was also reported that SIRT1 could limit 
replicative life span in response to chronic genotoxic stress. A recent study by Van der Veer and 
Figure 42 SIRT1 promotes tumorigenesis. Upon genotoxic stress, p53 is acetylated at K382, 
which enhanced DNA binding and transactivation activity. HIC1, miR34a, and DBC1 suppress 
SIRT1 activity. Multilayered inhibition of SIRT1 allows the activation status of p53 for p21, 
PUMA and BAX genes expression which induced cell cycle arrest, apoptosis, and senescence. 
Resveratrol and AROS, Along with other SIRT1 activators, enhance SIRT1 deacetylation on 
p53 and suppress p53 transcription-dependent cell cycle arrest and apoptosis by genotoxic 
stress (Biochim Biophys Acta. 2010 Aug;1804(8):1684-9) 
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colleagues186 demonstrated an extension of human vascular smooth muscle cell (SMC) lifespan by 
overexpression of Nampt, known to increase cellular NAD+ and caused increased SIRT1 activity and 
reduced fraction of p53 bearing acetylation on Lys382. Overexpression of Nampt resulted in deferred 
senescence and significantly prolonged lifespan, concomitant with enhanced SIRT1 activity. 
Increased SIRT1 activity represses p53 activity to prevent p53-dependent cellular senescence. Either 
SIRT1 overexpression or resveratrol increased the SIRT1 activity and inhibited the senescence and 
increased lifespam in many species including rodents187. Primary human mesenchimal stem cells 
(MSC) have a limited lifespan in vitro as any normal, somatic cell. After a certain number of cell 
divisions, MSC enter senescence, which is morphologically characterized by enlarged and irregular 
cell shapes and ultimately a stop of proliferation. The most used biomarker for senescent and aging 
cells is senescence-associated β-galactosidase(SA-β-gal), which identifies the senescent cells after 
cytoplasmatic coloration in blue color188, 189. 
Figure 43 β-Galactosidase assay in hMSC. (A) Percent of β-gal positive hMSC treated with RSV, 1c, 2c, or 3c 
at 50 µM for 48 h. (B) Optic microscope images (10X) of treated hMSC 
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From these data, we tested our SIRT activators 1c, 2c, and 3c (all used at 50 µM) in primary human 
mesenchimal stem cells (hMSC), to determine their potential protection against senescence. RSV (50 
µM) has been used 
as a reference drug.  
After 48 h of 
treatment, the 
number of β-
galactosidase 
positive cells, used 
as a marker of 
senescence, have 
been counted 
(Figure 43 A). Optic 
microscopy images 
(10X) of the cell 
cultures have been 
also obtained 
(Figure 43 B). In 
these conditions, considering the amount of senescent positive cells in the control population as 
100%, 1c, 2c, and 3c gave 60%, 70%, and 65% positive cells, respectively, in comparison with 50% 
positive cells by RSV. 
Figure 44  Model for PGC-1α transcriptional gene expression activity. 1) PGC-1α is 
part of multiprotein complexes that contain histone acetyl transferase activity that 
open and remodels chromatin to allow the transcription factor to bind DNA. In the 
transcriptional initiation complex SIRT1 would maintain deacetylated PGC-1α. 2) 
PGC-1α and its associated proteins will move with RNA processing, elongation 
factors and RNA polII to transcribe the mRNA. 3) After the mRNA processing, 
GCN5 would acetylate PGC-1α localizing the whole complex to a RIP140 containing 
subnuclear repressive foci. To initiate another cycle, SIRT1 would deacetylate PGC-
1α freeing it from the repressive foci, allowing it to become incorporated into protein 
complexes at promoter regions191 
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6.3. Sirtuins: Possible direct function in mitochondrial 
biogenesis 
The transcriptional co-activator PGC-1α and the NAD+-dependent deacetylase SIRT1 are considered 
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important inducers of mitochondrial biogenesis because in the nucleus they regulate transcription of 
Figure 45 Mitochondrial function in C2C12 myoblasts. (A) Fluorescence intensity of C2C12 
myoblasts treated for 16 h with DMSO (0), or increasing concentrations of 1c, or 50 µMRSV, and 
stained with Mitotracker Green. The data represent the values obtained after subtraction of the mean 
fluorescence background (unstained cells). (B) Scheme of the constructs carrying the wild type and 
mutant mTFA promoters. (C) Transcriptional activity of wild type (white bars) and mutant (black bars) 
mTFA promoter in C2C12 myoblasts treated for 16 h with increasing concentrations of 1c (left panel) 
and RSV (right panel). * p < 0.05, ** p < 0.01 versus DMSO (0) treated cells (Student’s t-test). 
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nucleus-encoded mitochondrial genes 190. 
By regulating peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α), through a 
functional protein-protein interaction, SIRT1 influences the activity of one of the most versatile 
metabolic transcriptional co-activators of genes involved in energy metabolism 191, 192. In particular, 
PGC-1α represents an upstream inducer of genes of mitochondrial metabolism by positively affecting 
the activity of some hormone nuclear receptors (peroxisome proliferator-activated receptor γ and 
estrogen-related receptor α) and nuclear transcription factors (NRF-1, 2) 193. NRF-1 is a downstream 
effector of SIRT1/PGC-1α and activates the expression of OxPhos components, mitochondrial 
transporters, and ribosomal proteins. Additionally, NRF-1 regulates the activation of the Tfam, 
Tfb1m, and Tfb2m promoters and indirectly affects the expression of Cox genes, Glut4 and PGC-1α 
itself 194. Importantly, the coordination of the two genomes seems to be exclusively achieved by the 
nucleus-encoded proteins TFAM 195 TFB1M, and TFB2M, among which the mitochondrial 
transcription factor A seems to play a central role being essential for transcription, replication, and 
maintenance of mtDNA 196, 197. RSV was reported to improve  mitochondrial function in skeletal 
muscle, largely due to PGC-1α activation 198, we tested the ability of our SIRT activator 1c to 
modulate mitochondrial function in murine C2C12 myoblasts. As shown in Figure 45 A, treatment 
with compound 1c for 16 h led to a significant increase of fluorescence intensity due to the 
mitochondrial specific probe Mitotracker Green, indicating increased mitochondrial density. The 
effect was similar to that observed with 50 µM RSV. Mitochondrial transcription factor A (mTFA) is 
crucial for mitochondrial DNA replication/transcription, and it was described that its expression 
replication/transcription, and it was described that its expression is controlled by transcription factors 
belonging to the nuclear respiratory factor (NRF) family and by PGC-1α 199. Therefore, it had been 
interesting to verify if 1c was able to improve mitochondrial biogenesis using the PGC-1α pathway. 
Thus using two different cell population, one with wild type mTFA promoter and the other one with 
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mutant mTFA promoter, it had been found that both compound 1c (Figure 45, left panel) and RSV 
(Figure 45, right panel) stimulated the promoter activity in a dose-dependent manner. The effect of 
both the SIRT activators is PGC-1α-dependent as the effect was not seen upon deletion of the NRF1 
site. 
6.4. Sirtuins and Calorie restriction 
Calorie restriction (CR) is a dietary regimen that extends the lifespan of every organism tested to 
date. SIRT1, may regulate many physiological processes known to be affected during aging and 
which are altered by CR. A recent study has shown that production of NO, stimulated by caloric 
restriction, increases SIRT1 expression; this study suggests that eNOS may be involved in regulation 
of the 
expression of 
SIRT1 in 
murine white 
adipocytes200. 
Importantly, 
SIRT1 had 
been 
recognized as a 
key regulator 
of vascular 
endothelial 
homeostasis, controlling angiogenesis, endothelial senescence, dysfunction 201-203, and increase in 
mitochondrial biogenesis (Nisoli et al. 2005). Moreover, this mitochondrial induction by CR does not 
occur in eNOS deficient mice. Interestingly, the SIRT1 gene is activated by NO in vivo and in vitro 
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Figure 46. 1c eNOS induction in HaCat cell line  
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(Nisoli et al. 2005), tracing a pathway in which CR induces NO production and activates 
mitochondrial biogenesis and SIRT1. In previous studies, it had been found that after treatment of 
human umbilical vein ECs (HUVEC) cell line with either an NO donor (such as DETA-NO or 
SNAP), expression of SIRT1 protein was markedly higher than that in untreated ones204 and that 
treatment with sirtinol or SIRT1siRNA itself promoted endothelial senescence by inhibiting SIRT1. 
Thus it had been interesting to test the effects on SIRT dependent NO production after treatment of 
HaCat cell line with SIRT activators. 1c was tested in a Nitric Oxide synthase activation assay. As the 
figure 46 shows, in HaCat cell line treated with 1c it was possible to see a dose-dependend NO 
production stronger than the NO donor DETA-NO, used as a reference, due to SIRT activation.  
6.5. Experimental Section 
6.5.1. Chemistry  
Melting points were determined on a Buchi 530 melting point apparatus and are uncorrected. Infrared 
(IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One instrument. 1H NMR and 13C 
NMR spectra were recorded at 400 MHz on a Bruker AC 400 spectrometer; chemical shifts are 
reported in δ (ppm) units relative to the internal reference tetramethylsilane (Me4Si). All compounds 
were routinely checked by TLC and 1H NMR. TLC was performed on aluminum-backed silica gel 
plates (Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light. All solvents were 
reagent grade and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator operating at reduced 
pressure of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulphate. Analytical 
results are within ±0.40% of the theoretical values.  All chemicals were purchased from Aldrich 
Chimica, Milan (Italy), or from Lancaster Synthesis GmbH, Milan (Italy), and were of the highest 
 PhD course in Pasteurian Sciences, XXIV cicle, Rome, 29th February, 2012 
 
78 6. Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and 
Inhibitors 
purity.  
The esters MC 2733, MC 2734, MC 2562 and MC 2735 were prepared by acid catalyzed reaction 
between benzaldehyde, ethyl propiolate and the opportune amine, afterwards these esters underwent 
alkaline hydrolysis to furnish the respective acid compounds MC 2736, MC2737, MC 2563 and MC 
2738 which reacted with triethylamine, Bop reagent and the appropriate amine to give finally the 
amides compounds MC 2743, MC 2744, MC 2566, MC 2745. 
6.5.1.1. General Procedure for the Synthesis of 1-aryl-(or arylalkyl, or cycloalkyl)-
diethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate. Example: synthesis of 1-
cyclopropyl-diethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (MC 2733). Ethyl 
propiolate (18.84 mmol, 1.9 mL), benzaldehyde (9.42 mmol, 0.96 mL) and cyclopropylamine (9.42 
mmol, 0.65 mL) in glacial acetic acid (0.5 mL) were heated at 80°C for 30 min. After cooling, the 
mixture was poured into water (20 mL) and stirred for 1 h. The solid product was filtered and washed 
with Et2O (3 x 30 mL) to give pure MC 2733 that was recrystallized by cyclohexane. 1H NMR (400 
MHz, CDCl3) δ 0.83-0.90 (m, 4H, cyclopropane protons), 1.14-1.17 (t, 6H, -OCH2CH3), 2.94-2.99 
(m, 1H, cyclopropane proton), 3.97-4.11 (q, 4H, -OCH2CH3), 4.83 (s, 1H, PhCH), 7.08-7.23 (m, 5H, 
benzene protons), 7.31 (s, 2H, dihydropyridine protons) ppm; 13C NMR (400 MHz, CDCl3) δ 6.10 
(2C), 14.20 (2C), 38.50, 44.50, 61.70 (2C), 108.0 (2C), 125.80, 128.70 (2C), 129.10 (2C), 142.20, 
146.10 (2C), 167.20 (2C) ppm; MS (EI): m/z: 341 (M)+. 
6.5.1.2. General Procedure for the Synthesis of 1-Aryl-(or arylalkyl, or cycloalkyl)-4-
phenyl-1,4-dihydropyridine-3,5-dicarboxylic Acids (2a-d). Example: 1-Phenethyl-4-
phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid (2d). A mixture of 1d (1.23 mmol, 0.5 g) 
and 5N KOH (6.15 mmol, 0.34 g, 1.23 mL) in ethanol (10 mL) was stirred at 80°C overnight. 
Afterward, the solvent was evaporated, the residue was eluted with water (30 mL) and the resulting 
solution acidified with 2N HCl. The obtained precipitate was filtered, washed by water (3 x 30 mL) 
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and dried to afford pure compound 2d, that was recrystallized by acetonitrile/methanol. 1H NMR 
(400 MHz, DMSO-d6) δ 2.95-2.99 (t, 2H, PhCH2CH2), 3.61-3.65 (t, 2H, PhCH2CH2), 4.82 (s, 1H, 
PhCH), 7.07-7.34 (m, 12H, benzene protons and dihydropyridine protons), 12.00 (bs, 2H, -COOH) 
ppm; 13C NMR (400 MHz, DMSO-d6) δ 42.00, 43.80, 57.70, 107.30 (2C), 125.70, 125.90, 127.70 
(4C), 128.60 (4C), 139.40, 144.40, 148.90 (2C), 171.30 (2C) ppm; MS (EI); m/z: 349 (M)+. 
6.5.1.3. General Procedure for the Synthesis of 1-aryl-(or arylalkyl, or cycloalkyl)-4-
phenyl-1,4-dihydropyridine-3,5-dicarboxamides. Example: synthesis of 1-phenyl-4-
phenyl-1,4-dihydropyridine-3,5-dicarboxamide (MC 2744). Triethylamine (10.38 mmol, 
1.44 mL) and BOP reagent (3.12 mmol, 1.38 g) were added under nitrogen atmosphere to a solution 
of compound MC 2737 (0.47 mmol, 0.150 g) in dry DMF (5mL), and the resulting mixture was 
stirred for 30 min at room temperature. After this time 33% aqueous ammonia (4.7 mmol, 0.27 mL) 
was added and the resulting mixture was stirring for further 30 min. The reaction was quenched by 
water (30 mL), the precipitate filtered was washed with water (3 x 30 mL) and  Et2O (3 x 30 mL) to 
provide MC 2744 that was recrystallized by acetonitrile/methanol. 1H NMR (DMSO-d6) δ 5.07 (s, 
1H, PhCH), 6.73 (bs, 4H, -CONH2), 7.02-7.53 (m, 12H, benzene protons and dihydropyridine 
protons) ppm; 13C NMR (400 MHz, DMSO-d6) δ 45.10, 110.20 (2C), 116.30 (2C), 118.80, 125.80, 
128.70 (2C), 129.60 (2C), 138.10 (2C), 141.30, 142.20, 171.0 (2C) ppm; MS (EI): m/z: 319 (M)+.  
6.5.2. Biological assays  
6.5.2.1.  SIRT Assay. Modulation of sirtuin activity by compounds was assessed using the Fluor de 
Lys fluorescent biochemical assay available through BioMol International, LP in 96-well format. In 
the first part of a two-step reaction, an acetylated lysine side chain present on the substrate is 
deacetylated during incubation at 37 ͦC for an hour with active enzyme (SIRT1, SIRT2, or SIRT3), 
compounds 1-3, and NAD þin white, 96-well polystyrene luminescence plates (Perkin Elmer- 
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6005680). The latter half of the reaction produces a fluorophore upon treatment with a developing 
reagent. The reaction is read by a Perkin-Elmer Victor2V 1420 Multilabel Counter plate reader with 
filters that excite at 355 nm and detect emitted light at 460 nm with a read time of 0.1s per well. 
Sirtuin 1 enzyme (BioMol-SE-239) is a 747 amino acid protein with a molecular weight of 82 kDa, 
while Sirtuin 2 enzyme (BioMol-SE-251) is a 389 amino acid protein with a molecular weight of 43 
kDa; both were purified from human cDNA expressed in Escherichia coli and stored in 25 mM Tris, 
pH 7.5, 100 mM NaCl, 5 mM DTT, and 10% glycerol. Sirtuin 3 enzyme (BioMol-SE-270) is inactive 
prior to removal of its Nterminus, thus this assay only utilizes the catalytically active fragment 
spanning amino acids 102-299 with a molecular weight of 32.7 kDa. Like sirtuins 1 and 2, the 
fragment was purified from cDNA expressed in E. coli and stored in 25 mM Tris, pH 7.5, 100 mM 
NaCl, 5 mM DTT, and 10% glycerol. While there is variability in activity among individual lots, each 
experiment normalizes SIRT1 activity to 1U/reaction well and SIRT2 and SIRT3 activity to 
5U/reaction well (where U=1 pmol/min at 37 ͦC, 250 µMsubstrate, and 500 µMNAD β). All reagents 
are diluted on ice in the following reaction buffer: 50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM 
KCl, 1 mM MgCl2, and 1 mg/mL BSA. Thus for each reaction well, the requisite amount of enzyme 
(as detailed above) is added to 500 µM NADβ (BioMol-KI-282), 250 µM fluorgenic deacetylase 
substrate (BioMol-KI-177), and the compound of interest at a given concentration in a total reaction 
volume of 50 µL. After an hour incubation at 37 ͦC, the reaction is stopped upon addition of 1x 
Developer (BioMol-KI-176) for a final reaction volume of 100 µL. The reaction is incubated at 37 ͦC 
for an additional 15 min and then read on the plate reader. Experimental replicates were done in 
triplicate with appropriate controls. Positive controls contained only enzyme, substrate, NAD β, and 
DMSO while background controls contained substrate, NADβ, and DMSO only. Autofluorescent 
controls were also included for testing of activators and included substrate, NAD β, and the 
compound at the same concentration as its experimental counterpart. Background signal was 
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subtracted from positive control well signals, and autofluorescent background was subtracted from 
experimental well signals at all tested compound doses.  
6.5.2.2. Determination of α-Tubulin Specific Acetylation. For α-tubulin acetylation studies, 
50 µg of total protein extracts (U937 cells) were separated on a 10% polyacrylamide gels and 
blotted.51 Western blots were shown for acetylated α-tubulin (Sigma, dilution 1:500) and total ERKs 
(Santa Cruz) were used to normalize for equal loading 
6.5.2.3. Cell Cycle Analysis on U937 Cells. First, 2.5x 105 cells were collected and resuspended 
in 500 µL of a hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 50 µg/mL propidium 
iodide (PI), RNase A). Then cells were incubated in the dark for 30 min. Samples were acquired on a 
FACS-Calibur flow cytometer using the Cell Quest software (Becton Dickinson) and analyzed with 
standard procedures using the Cell Quest software (Becton Dickinson) and the ModFit LT version 3 
Software (Verity) as previously reported163. All experiments were completed in triplicate. 
6.5.2.4. FACS Analysis of Apoptosis on U937 Cells. Apoptosis was measured with the caspase 
3-7 detection (B-Bridge) method; samples were analyzed by FACS with Cell Quest technology 
(Becton Dickinson) as previously reported164. 
6.5.2.5. Granulocytic Differentiation on U937 Cells. Granulocytic differentiation was carried 
out as previously described164. U937 cells were harvested and resuspended in 10 µL 
phycoerythrineconjugated CD11c (CD11c-PE). Control samples were incubated with 10 µL of PE 
conjugated mouse IgG1, incubated for 30 min at 4 ͦC in the dark, washed in PBS, and resuspended in 
500 µL of PBS containing PI (0.25 µg/mL). Samples were analyzed by FACS with Cell Quest 
technology (Becton Dickinson). PI positive cells have been excluded from the analysis. 
6.5.2.6. β-Galactosidase Assay. For this assay, we used 3 x 105 cells/ well. Human primary 
mesenchimal stem cells have been kept in culture for 30 days (corresponding to the ninth passage) 
before starting the experiment. Cultured cells were washed in PBS and fixed with 2% (w/v) 
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formaldehyde and 0.2% (w/v) glutaraldehyde solution. Cells were then washed with PBS and 
incubated overnight at 37 ͦC in freshly prepared staining buffer (30 mM citric acid/ phosphate buffer 
(pH 6), 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 150mMNaCl, 2 mMMgCl2, 1 mg/mL X-Gal). At the 
end of incubation, cells were washed with PBS and examined under the microscope. The percent of 
senescent cells was calculated by counting the number of blue cells (positive cells) out of total 
cells188. 
6.5.2.7. Mitochondrial Density in Murine C2C12 Myoblasts. Murine C2C12 myoblasts 
were plated in 96-well clusters (3000 cells/ well) and treated overnight with the compounds under 
investigation. Mitochondria were stained with the Mito-Tracker Green FM dye (200 nM) from 
Molecular Probes (Invitrogen, Milan, Italy). Fluorescence intensities were measured using the 
EnVision multilabel reader platform (PerkinElmer, Italia Spa, Monza, Italy). The data shown 
represent the values obtained after subtraction of the mean fluorescence background measured in 
wells with unstained cells. 
6.5.2.8. Transcriptional Activity of mTFA-Promoter in Murine C2C12 Myoblasts. 
Murine C2C12 myoblasts (CRL-1772, ATCC, Teddington, UK) were grown in Dulbecco’s Modified 
Eagle’s Medium supplemented with 10% heat inactivated fetal calf serum. Cells were 
retrotransfected with the plasmids bearing either the mTFA-promoter or the mutated form lacking the 
NRF1 binding site205, fused to the luciferase gene. Lipofectamine (Invitrogen, Milan, Italy) was used 
as transfecting reagent (2.5 µL/µg DNA). Transfected cells were then plated in 96-well clusters (3000 
cells/well) and treated overnight with the compounds under investigation. The luciferase activity was 
measured using the EnVision multilabel reader platform (PerkinElmer Italia Spa, Monza, Italy). The 
constructs used in the transfection assays were first validated overexpressing PGC-1α or SIRT1. In 
both conditions the wild type promoter was stimulated by 2-3 fold, whereas the mutant promoter 
lacking the NRF1 binding site did not respond. 
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6.5.2.9. Nitric Oxide synthase activation assay. NO production was measured with the DAF-2 DA 
detection method. DAF-2 DA is a cell permeable fluorescent probe for NO detection. It was used to 
load cells, subsequent hydrolysis by cytosolic esterases released DAF-2, which is relatively non-
fluorescent at physiological pH, however in the presence of NO DAF-2 is converted to the 
fluorescent triazole derivative, DAF-2T. After samples were analyzed by FACS. 
7. Biochemical, Structural, and Biological Evaluation of 
Tranylcypromine Derivatives as Inhibitors of Histone 
Demethylases LSD1 and LSD2 
LSD1 and LSD2 share a similar catalytic domain (45% sequence identity) that is structurally 
homologous with the amine oxidases, a class of flavin-dependent enzymes that act on biogenic 
amines 206, 207. Among these proteins, human monoamine oxidases (MAOs) A and B have been the 
subject of more than 50 years of research that has led to the development of a multitude of inhibitors 
including antidepressive and antiparkinson drugs 208. Their similarity in the catalytic and structural 
properties prompted the investigation of antiMAO drugs as potential LSD1 inhibitors 209. It was 
found that tranylcypromine, a MAO inhibitor used as antidepressive drug, is able to inhibit LSD1210-
213
. On this basis, it had been interesting to design compounds that would be more selective for 
demethylases using tranylcypromine as the lead scaffold.  
Tranylcypromine is a racemic mixture of (()-trans-2-phenylcyclopropyl-1-amine ·  HCl (tPCPA) that 
covalently inhibits the LSD and MAO enzymes. The aim of this project had been to study the 
tranylcypromine in order to verify the presence of possible enantio-selective inhibitory activity and, 
once got this information, to design new compounds tranylcypromine-like in order to improve the 
first results. 
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7.1. Chemistry 
The syntheses of (±)-trans-2-phenylcyclopropyl-1-amine (tPCPA), (±)-cis-2-phenylcyclopropylamine 
(cPCPA), (±)-trans-2-(4-bromophenyl)cyclopropyl-1-amine (Br-tPCPA), and (±)-cis-2-(4-
bromophenyl)cyclopropylamine (Br-cPCPA) and their hydrochlorides were performed by a variety of 
methods, but in some cases a confusion occurred between the various diastereoisomers and the 
mixtures of them (1-9). To follow an unambiguous pathway of synthesis, we prepared the 
Scheme 3. a) EDA, CuCl, dry CHCl3, 60 °C, N2 atmosphere; b) 2 N KOH, EtOH, rt; c) 1) 
DPPA, Et3N, dry t-BuOH, dry benzene, 80 °C, N2 atmosphere; 2) Boc2O, dry benzene, 80 °C, 
N2 atmosphere; d) 6 N HCl, THF, rt; e) 2 N K2CO3, NaH2PO2, Pd/C, THF, 60 °C, N2 
atmosphere. 
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unsubstituted, 4-bromo-, and 4-nitro-2-phenylcyclopropyl-1-amine derivatives according to Scheme 
1, following the procedure described by Rosen et al. (J Med Chem 47, 5860-5871.). Trans and cis 
ethyl 2-phenylcyclopropylcarboxylates (2a-c and 3a-c) were synthesized by treating the appropriate 
styrene derivatives 1a-c with ethyl diazoacetate (EDA) in the presence of copper (I) chloride (CuCl) 
in dry CHCl3. Alkaline hydrolysis of 2a-c and 3a-c furnished the corresponding carboxylic acids 4a-c 
and 5a-c, which were in turn converted into the related t-butoxy carbamates 6a-c and 7a-c through 
reaction with diphenylphosphoryl azide and t-butanol in the presence of trietylamine in dry benzene. 
Acidic hydrolysis (6 N HCl) of 6a, b and 7a, b yielded tPCPA·HCl and Br-tPCPA·HCl (from 6a and 
6b), and cPCPA·HCl and Br-cPCPA·HCl (from 7a and 7b). Reduction of the nitro group of 6c and 
7c with sodium hypophosphite, palladium on carbon, and potassium carbonate afforded the related 4-
aminophenyl carbamates 8 and 9 (Scheme 3). 
The enantiomers of (±)-tPCPA HCl, (±)-cPCPA HCl, (±)-Br-tPCPA HCl, and (±)-Br-cPCPA HCl 
were obtained by the following two-step procedure: 1) direct multi-mg enantioseparation of their N-
tert-butoxycarbonyl (Boc)- intermediates 6a,b and 7a,b by HPLC on polysaccharide-based chiral 
stationary phases (CSPs); 2) cleavage of the Boc group of the isolated enantiomers using 6 N HCl.  
7.2. Preparation and absolute configuration assignment of the 
enantiomers of Br-cPCPA HCl. 
The enantiomers of 7b were separated on a semipreparative scale by enantioselective HPLC on the 
Chiralcel OD CSP using the mixture n-hexane-ethanol 97:3 (v/v) as eluent. The chromatographic data 
were: k1 = 1.14; k2 = 1.62;  = 1.42; amount of sample resolved in a single semipreparative run = 6 
mg; injection volume = 0.4 ml; flow rate = 5.0 ml/min, detector = UV at 260 nm; temperature = 25 
°C. k1: retention factor of the first eluted enantiomer, defined as (t1 – t0)/t0 where t0 is the void time of 
the column; : enantioselectivity factor defined as k2/k1. Polarimetric analysis indicated that the first 
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eluted enantiomer on the OD CSP rotated the polarized light in the negative direction in ethanol 
solution { -148 (c: 0.1, ethanol), ee>99%}, whereas the second eluted enantiomer was 
dextrorotatory { +146 (c: 0.1, ethanol), ee>99%}. Suitable crystals for X-ray analysis were 
obtained for the dextrorotatory enantiomer (second eluted on the OD CSP) which allowed the 
determination of the (1R,2R) absolute configuration (AC) [(1R,2R)-(+)-7b] (Figure 45). Therefore its 
levorotatory enantiomer had the (1S,2S) AC [(1S,2S)-(-)-7b].  
The isolated pure enantiomers of 7b were 
converted to the corresponding Br-cPCPAs 
hydrochlorides by treatment with 6 N HCl 
(see Scheme 3). Thus starting from 
optically pure of known (1R,2R) or (1S,2S) 
AC, optically pure (enantiomeric excess, 
ee>99%) forms of (+)- and (-)-Br-cPCPA 
HCl with the same AC were obtained. The 
enantiomeric purity was determined by 
enantioselective HPLC on the Chiralcel OJ 
CSP using the mixture n-hexane-2-
propanol-diethylamine 90:10:0.1 (v/v/v) as 
mobile phase. The chromatographic data 
were: k1 = 1.44; k2 = 1.76;  = 1.22; flow rate = 1.0 ml/min; detector = UV at 254 nm; temperature = 
25°C. The single enantiomers of Br-cPCPA HCl were characterized as follows: first eluted 
enantiomer on the OJ CSP: AC: (1R,2R), -57 (c: 0.1, H2O), ee>99% {(1R,2R)-(-)-Br-cPCPA 
[ ]20Dα
[ ]20Dα
[ ]20Dα
Figure 47. An ORTEP view of the molecular structure of the 
(1R,2R)-(+)-7b enantiomer. 
